<article article-type="review-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Reg Anesth Pain Med</journal-id><journal-id journal-id-type="iso-abbrev">Reg Anesth Pain Med</journal-id><journal-id journal-id-type="pmc-domain-id">694</journal-id><journal-id journal-id-type="pmc-domain">bmjgroup</journal-id><journal-id journal-id-type="publisher-id">rapm</journal-id><journal-title-group><journal-title>Regional Anesthesia and Pain Medicine</journal-title></journal-title-group><issn pub-type="ppub">1098-7339</issn><issn pub-type="epub">1532-8651</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>BMJ Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12911631</article-id><article-id pub-id-type="pmcid-ver">PMC12911631.1</article-id><article-id pub-id-type="pmcaid">12911631</article-id><article-id pub-id-type="pmcaiid">12911631</article-id><article-id pub-id-type="pmid">40602807</article-id><article-id pub-id-type="doi">10.1136/rapm-2025-106718</article-id><article-id pub-id-type="publisher-id">rapm-2025-106718</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Practice advisory for intravenous management of headache disorders in hospitalized patients: a review of the evidence and consensus recommendations</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-0893-8813</contrib-id><name name-style="western"><surname>Hoydonckx</surname><given-names initials="Y">Yasmine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feoktistov</surname><given-names initials="A">Alexander</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Amoozegar</surname><given-names initials="F">Farnaz</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anderson</surname><given-names initials="CC">Christopher C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barad</surname><given-names initials="M">Meredith</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burke</surname><given-names initials="E">Emeralda</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chitsantikul</surname><given-names initials="P">Prin</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-5011-3298</contrib-id><name name-style="western"><surname>Doshi</surname><given-names initials="TL">Tina L</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-2199-1056</contrib-id><name name-style="western"><surname>Englesakis</surname><given-names initials="M">Marina</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goel</surname><given-names initials="A">Akash</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gupta</surname><given-names initials="H">Himanshu</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kissoon</surname><given-names initials="N">Narayan</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kirschner</surname><given-names initials="A">Aaron</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-0407-806X</contrib-id><name name-style="western"><surname>Kohan</surname><given-names initials="L">Lynn</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lauritsen</surname><given-names initials="CG">Clinton G</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="F">Franziska</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Monsour</surname><given-names initials="D">Danny</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-9874-5507</contrib-id><name name-style="western"><surname>Nader</surname><given-names initials="A">Antoun</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ogunlaja</surname><given-names initials="O">Oyindamola</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schuster</surname><given-names initials="N">Nathaniel</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-3464-4149</contrib-id><name name-style="western"><surname>Schwenk</surname><given-names initials="ES">Eric S</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silberstein</surname><given-names initials="SD">Stephen D</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Souza</surname><given-names initials="D">Dmitri</given-names></name><xref ref-type="aff" rid="aff17">17</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-4536-9974</contrib-id><name name-style="western"><surname>Yuan</surname><given-names initials="H">Hsiangkuo</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Narouze</surname><given-names initials="S">Samer</given-names></name><xref ref-type="aff" rid="aff18">18</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Anesthesiology and Pain Medicine</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Institute of Health Policy Management and Evaluation</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff><aff id="aff3"><label>3</label><institution>Synergy Integrative Headache Center</institution>, <addr-line content-type="city">Northfield</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff><aff id="aff4"><label>4</label><institution content-type="department">Clinical Neurosciences</institution>, <institution>University of Calgary Cumming School of Medicine</institution>, <addr-line content-type="city">Calgary</addr-line>, <addr-line content-type="state">Alberta</addr-line>, <country>Canada</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Neurology and Pain Management</institution>, <institution>Ochsner Health Center</institution>, <addr-line content-type="city">Covington</addr-line>, <addr-line content-type="state">Louisiana</addr-line>, <country>USA</country></aff><aff id="aff6"><label>6</label><institution content-type="department">Anesthesiology, Perioperative and Pain Medicine</institution>, <institution>Stanford Hospital and Clinics</institution>, <addr-line content-type="city">Redwood</addr-line>, <addr-line content-type="state">California</addr-line>, <country>USA</country></aff><aff id="aff7"><label>7</label><institution>Unity Health Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff><aff id="aff8"><label>8</label><institution content-type="department">Anesthesiology and Critical Care Medicine</institution>, <institution>Johns Hopkins University</institution>, <addr-line content-type="city">Baltimore</addr-line>, <addr-line content-type="state">Maryland</addr-line>, <country>USA</country></aff><aff id="aff9"><label>9</label><institution content-type="department">Library &amp; Information Services</institution>, <institution>University Health Network</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff><aff id="aff10"><label>10</label><institution content-type="department">Neurology</institution>, <institution>University of Toronto </institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff><aff id="aff11"><label>11</label><institution content-type="department">Neurology &amp; Anesthesiology</institution>, <institution>Mayo Clinic</institution>, <addr-line content-type="city">Rochester</addr-line>, <addr-line content-type="state">Minnesota</addr-line>, <country>USA</country></aff><aff id="aff12"><label>12</label><institution content-type="department">Anesthesiology</institution>, <institution>University of Virginia School of Medicine</institution>, <addr-line content-type="city">Charlottesville</addr-line>, <addr-line content-type="state">Virginia</addr-line>, <country>USA</country></aff><aff id="aff13"><label>13</label><institution content-type="department">Jefferson Headache Center -Neurology</institution>, <institution>Thomas Jefferson University</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff><aff id="aff14"><label>14</label><institution content-type="department">Anesthesiology</institution>, <institution>Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff><aff id="aff15"><label>15</label><institution content-type="department">Anesthesiology</institution>, <institution>UC San Diego Health</institution>, <addr-line content-type="city">San Diego</addr-line>, <addr-line content-type="state">California</addr-line>, <country>USA</country></aff><aff id="aff16"><label>16</label><institution content-type="department">Anesthesiology and Perioperative Medicine</institution>, <institution>Thomas Jefferson University</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff><aff id="aff17"><label>17</label><institution content-type="department">Pain Medicine</institution>, <institution>Western Reserve Hospital Partners</institution>, <addr-line content-type="city">Cuyahoga Falls</addr-line>, <addr-line content-type="state">Ohio</addr-line>, <country>USA</country></aff><aff id="aff18"><label>18</label><institution content-type="department">Anesthesiology</institution>, <institution>Case Western Reserve University</institution>, <addr-line content-type="city">Cleveland</addr-line>, <addr-line content-type="state">Ohio</addr-line>, <country>USA</country></aff></contrib-group><author-notes><fn><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn id="fn1"><p>Additional supplemental material is published online only. To view, please visit the journal online (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/rapm-2025-106718" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1136/rapm-2025-106718</ext-link>).</p></fn><fn fn-type="COI-statement" id="fn4"><p>YH: Research grants from the Canadian Pain Society (CPS) and the American society of Regional Anesthesia and Pain Medicine (ASRA-PM) for the KetHead study 'A Multi-Center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches: The KetHead Study.' AF: President and Board member of the American Interventional Headache Society FA: Research grants from the Canadian Institute of Health Research, Spinal CSF Leak Canada, and has also been the principal investigator of multiple studies funded by Abbvie, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva. Received honoraria for consulting or speaking from Abbvie, Aralez, Eli Lilly, ICEBM, Lundbeck, Novartis, Pfizer and Teva. CCA: No competing interests to declare MB: Consultant for Eli Lilly and Altamont Medical EB: No competing interests to declare. PC: Received speakers’ honoraria from the college of family physicians of Alberta, and Teva Pharmaceutical. TLD: No competing interests to declare. ME: No competing interests to declare. AG: No competing interests to declare. HG: No competing interests to declare. NK: Consultant for Vertex Pharmaceuticals and receives royalties from UpToDate, Inc AK: No competing interests to declare. LK: Funded institutional research from FUS Mobile, Avertias, Vertex, Avanos. Consulting Avanos. CGL: No competing interests to declare. FM: No competing interests to declare. DM: Speaker/Consultant for Searchlight/Miravo, Lundbeck, Abbvie, Novartis, Eli Lilly, Teva, Pfizer, LinPharma AN: No competing interests to declare. OO: No competing interests to declare. NS: Received research funding from Migraine Research Foundation, ShiraTronics, NINDS U24 NS115714, NINDS 3OT2NS122680-01S3, NCCIH 5R00AT009466-04, NIH CTSA Grant UL1TR000100, UCSD Academic Senate, and UCSD Department of Anesthesiology RAG, and has been a consultant for Averitas, Lohocla, Rapport, Salvia, Schedule 1 Therapeutics, and Vertex. He serves on the editorial board of Pain Medicine (Oxford University Press) and Interventional Pain Medicine (Elsevier). ESS: Receives annual royalties from UpToDate SDS: Principal Investigator in a clinical trial for Johnson &amp; Johnson, and an advisor for AbbVie Satsuma and Axsome. DS: Member of the AbbVie Speaker bureau. HY: Grants (AHS Early-Stage Investigator Research Award, 2024). Site investigators: Teva, Abbvie, Ipsen, Parema, Pfizer, Shiratronics, Johnson &amp; Johnson. Consultants/Advisory Board: Salvia, Pfizer, Abbvie, Cerenovous. Royalties: Cambridge University Press, Medlink. Lecture/travel awards: Chinese Stroke Association, American Headache Society SN: Consultant with Shiratonics and Executive Board Member for ASRA Pain Medicine.</p></fn><corresp id="cor1">Dr Yasmine Hoydonckx; <email xlink:href="yasmine.hoydonckx@uhn.ca" xmlns:xlink="http://www.w3.org/1999/xlink">yasmine.hoydonckx@uhn.ca</email></corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>02</day><month>7</month><year>2025</year></pub-date><volume>51</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">507819</issue-id><elocation-id>e106718</elocation-id><history><date date-type="received"><day>02</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>18</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 10:25:12.893"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © American Society of Regional Anesthesia &amp;amp; Pain Medicine 2026. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ Group.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref content-type="ccbynclicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="rapm-51-2.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri xlink:href="rapm-51-2.pdf" xlink:title="pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Patients hospitalized for headache treatment pose unique challenges to the healthcare system. Currently, there is a lack of evidence-based guidance on management. This practice advisory aims to fill this critical gap by systematically reviewing the existing literature and providing comprehensive, evidence-based recommendations for managing headache patients during hospitalization.</p></sec><sec><title>Methods</title><p>In February 2023, the American Society of Regional Anesthesia and Pain Medicine approved this practice advisory proposal. The steering committee selected committee members based on clinical and research expertise in the field of headache medicine. Nine questions were formulated by the committee, and each question was assigned to a group composed of 3–4 members. A systematic literature search for each question was performed in Medline, Embase, Cochrane Database of Systematic Reviews and Web of Science on June 21, 2023. The results from each search were imported into separate Covidence projects for screening, data extraction, and risk of bias assessment. Additionally, relevant systematic reviews (SR) were screened. Each group submitted a structured narrative review along with statements and recommendations based on the US Preventive Services Task Force (USPSTF) format for grading of evidence. While the USPSTF framework was used, including the language in the recommendations, the formal USPSTF methodology, including the SR with meta-analysis and summary tables with forest plots, was not followed because of low overall evidence quality. The interim draft was shared electronically with each collaborator, who was requested to vote anonymously using two rounds of the modified Delphi approach. A consensus recommendation required &gt;75% agreement.</p></sec><sec><title>Results</title><p>The panel generated 12 statements and 17 recommendations, along with their strength and certainty of evidence. Following two rounds of Delphi voting, a high consensus was achieved for all statements and recommendations. Most statements received a low-to-moderate level of certainty, and all but one recommendation received grade B or C, which was consistent with the lack of randomized controlled trials supporting most of the drugs in this document.</p></sec><sec><title>Conclusions</title><p>This evidence-based practice advisory provides a foundational step toward standardizing inpatient headache care and highlights existing gaps in the literature that should be addressed through rigorous prospective randomized studies.</p></sec></abstract><kwd-group><kwd>Headache</kwd><kwd>Pain Management</kwd><kwd>Treatment Outcome</kwd><kwd>CHRONIC PAIN</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" orientation="portrait" position="float"><sec><title>WHAT IS ALREADY KNOWN ON THIS TOPIC</title><list list-content="ul" list-type="bullet"><list-item><p>Management of hospitalized patients with refractory headache is challenging, and current guidelines are primarily focused on the outpatient population, leaving a knowledge gap when it comes to evidence-based management strategies.</p></list-item></list></sec><sec><title>WHAT THIS STUDY ADDS</title><list list-content="ul" list-type="bullet"><list-item><p>This practice advisory provides an up-to-date, evidence-based review of the most commonly used intravenous medications for inpatient refractory headache treatment.</p></list-item></list></sec><sec><title>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY</title><list list-content="ul" list-type="bullet"><list-item><p>The assessments and recommendations contained in this document demonstrate that there are multiple potentially effective treatments for refractory headache, and yet there is a great need for additional randomized, double-blind trials that evaluate many of these promising drugs.</p></list-item></list></sec></boxed-text><sec id="s1" sec-type="intro"><title>Introduction</title><p> The prevalence and burden of migraine and other primary headaches in the US adult population are significant. Headache is the fifth most common reason for emergency department (ED) visits, accounting for approximately 3% of all annual ED visits.<xref ref-type="bibr" rid="R1"><sup>1</sup></xref> Approximately 0.2% of patients fail to respond to initial ED treatment and require hospitalization to effectively manage pain.<xref ref-type="bibr" rid="R2"><sup>2</sup></xref> Patients hospitalized for headache treatment have an average length of hospitalization of 5 days±1.1 SD (range 2–9), resulting in a total annual cost of US$400 million.<xref ref-type="bibr" rid="R2"><sup>2 3</sup></xref></p><p>Outpatient headache treatment typically includes mostly oral medications, while intravenous infusions are more commonly used in emergency and inpatient settings.<xref ref-type="bibr" rid="R4"><sup>4</sup></xref> Intravenous administration offers many advantages, including faster onset, improved bioavailability, and potentially greater effectiveness.</p><p>Despite extensive literature on pharmacological treatments for primary headache disorders, there is little guidance on the management of the unique challenges of hospitalized patients with headache.<xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R6">6</xref> The refractory nature and complexity of this pathology, coupled with its socioeconomic impact, underscore the urgent need for targeted research and evidence-based guidance. Additionally, many healthcare providers across specialties report limited knowledge regarding effective inpatient headache management.<xref ref-type="bibr" rid="R7"><sup>7 8</sup></xref> This practice advisory aims to fill this critical gap by providing evidence-based recommendations for managing headache patients during hospitalization.</p><p>This document does not establish a standard of care or replace clinical judgment. It does not intend to limit or deny care, affect the rights of patients or providers, or replace clinical judgment. In the imperfect setting of heterogeneous data, limited data, controversial topics, and bias inherent to expert opinion, compliance with the recommendations may not result in improved outcomes compared with personalized medicine.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><p>The start of this project began with the submission of a proposal to the American Society of Regional Anesthesia and Pain Medicine (ASRA PM) in February 2023. The proposal was reviewed and approved by the Board of Directors. The steering committee (YH, AF, and SN) selected diverse committee members based on clinical and research expertise in the field of headache management (neurologists, pain physicians, anesthesiologists, pain/headache fellowship directors, and a patient representative). Based on the input from all committee members during a virtual meeting on May 30, 2023, the committee selected nine questions that were confirmed. The steering committee assigned 3–4 members to each question based on their expertise, and one person from each group was designated as a group leader. A health sciences librarian conducted a systematic literature search for each question in MEDLINE, Embase, Cochrane Database of Systematic Reviews (SR), and Web of Science on June 21, 2023. The search block for the ‘infusion’ concept and ‘primary headache’, common to all searches, was combined with each specific ‘drug’ (<xref ref-type="supplementary-material" rid="SP1">online supplemental appendix A</xref>). All types of studies were accepted, except for research in progress, abstracts, and book chapters. A publication date limit of 1999 onwards wasset by the committee, as it was deemed the start of increasing recognition and research of headache. The search was further limited to English language and human subjects of age 18 and above. While studies that included hospitalized patients were prioritized, studies that included patients in the ED were also retrieved and permitted in the consensus discussions if there was a lack of inpatient studies. Questions for which ED studies were permitted are clearly indicated within the responses. Each search result was imported into its own Covidence project for the purposes of deduplication and screening. Each group member independently conducted title, abstract, and full-text screening of the included studies, followed by data extraction in Word tables. Additionally, each group was asked to screen the references of SR relevant to their topic to ensure no critical studies were overlooked. Risk of bias assessment and strength of evidence evaluation across domains were performed (<xref ref-type="supplementary-material" rid="SP2">online supplemental appendix B</xref>). Each group submitted their findings in the form of a structured narrative review. Recommendations for each topic were formed using the framework of the US Preventive Services Task Force (USPSTF) grading of evidence guidelines.<xref ref-type="bibr" rid="R9"><sup>9</sup></xref> The grade of evidence was classified as A, B, C, D, or I and was based on group consensus rather than predetermined USPSTF rules because of the flexibility needed in light of the overall low quality of evidence (<xref ref-type="table" rid="T1">table 1</xref>). Statements were assigned a level of certainty (<xref ref-type="table" rid="T2">table 2</xref>). Each group’s submission was reviewed and revised by the steering committee (YH, AF, and SN). The interim draft was shared with all committee members electronically, and they were requested to vote anonymously on each recommendation using a modified Delphi approach.<xref ref-type="bibr" rid="R10"><sup>10</sup></xref> We used Microsoft Excel (Microsoft, Redmond, Washington, USA) for two rounds of electronic voting. Each member was requested to ‘agree’, ‘disagree’ or ‘abstain’ from each statement or recommendation.<xref ref-type="bibr" rid="R11"><sup>11</sup></xref> Collaborators were also invited to provide narrative comments and reasons for their decision if they disagreed or abstained.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>US Preventive Services Task Force (USPSTF) grade definitions<xref ref-type="table-fn" rid="T1_FN1">*</xref></title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" rowspan="1" valign="bottom">Grade definition suggestions for practice</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="top">A</td><td align="left" colspan="1" rowspan="1" valign="top">The USPSTF recommends the service. There is high certainty that the net benefit is substantial.</td><td align="left" colspan="1" rowspan="1" valign="top">Offer or provide this service.</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">B</td><td align="left" colspan="1" rowspan="1" valign="top">The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or there is moderate certainty that the net benefit is moderate to substantial.</td><td align="left" colspan="1" rowspan="1" valign="top">Offer or provide this service.</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">C</td><td align="left" colspan="1" rowspan="1" valign="top">The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.</td><td align="left" colspan="1" rowspan="1" valign="top">Offer or provide this service for selected patients depending on individual circumstances.</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">D</td><td align="left" colspan="1" rowspan="1" valign="top">The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.</td><td align="left" colspan="1" rowspan="1" valign="top">Discourage the use of this service.</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">I</td><td align="left" colspan="1" rowspan="1" valign="top">The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.</td><td align="left" colspan="1" rowspan="1" valign="top">Read the clinical considerations section of USPSTF Recommendation Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T1_FN1"><label>*</label><p><ext-link ext-link-type="uri" xlink:href="https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-</ext-link>definitions.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Levels of certainty regarding net benefit<xref ref-type="table-fn" rid="T2_FN1">*</xref></title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1" valign="bottom">Level of description<break/>certainty</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="top">High</td><td align="left" colspan="1" rowspan="1" valign="top">The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Moderate</td><td align="left" colspan="1" rowspan="1" valign="top">The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as:<break/>The number, size, or quality of individual studies. Inconsistency of findings across individual studies.<break/>Limited generalizability of findings to routine primary care practice. Lack of coherence in the chain of evidence.<break/>As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Low</td><td align="left" colspan="1" rowspan="1" valign="top">The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of:<break/>The limited number or size of studies. Important flaws in study design or methods.<break/>Inconsistency of findings across individual studies. Gaps in the chain of evidence.<break/>Findings not generalizable to routine primary care practice. Lack of information on important health outcomes.<break/>More information may allow estimation of effects on health outcomes.</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T2_FN1"><label>*</label><p>The USPSTF defines certainty as ‘likelihood that the USPSTF assessment of the net benefit of a preventive service is correct’. The net benefit is defined as benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature of the overall evidence available to assess the net benefit of a preventive service.</p></fn><fn fn-type="abbr"><p>USPSTF, US Preventive Services Task Force.</p></fn></table-wrap-foot></table-wrap><p>After the first round of voting, all statements and recommendations obtained &gt;80% consensus. Recommendations with 100% agreement were accepted, as well as those recommendations with &gt;85% agreement that only needed grammatical improvement. All other statements and recommendations were revised by the steering committee considering contributors’ comments and sent back for a second voting round with the aim to increase consensus in the second round. In the second round, statements and recommendations with a predefined &gt;75% agreement were accepted. Both USPSTF grading and &gt;75% agreement threshold have been previously used in ASRA PM consensus guidelines.<xref ref-type="bibr" rid="R12"><sup>12 13</sup></xref> Language was further refined considering contributors’ comments. The subsequent draft was shared with all the collaborators for final approval.</p></sec><sec id="s3" sec-type="results"><title>Results</title><p>The results retrieved from our systematic literature search for each drug are shown in <xref ref-type="supplementary-material" rid="SP1">Online supplemental appendix</xref>.</p><p>After two rounds of voting, all statements and recommendations were approved by &gt;85% consensus. The final manuscript was approved by all committee members and ASRA PM Board of Directors. The statements and recommendations are summarized in <xref ref-type="table" rid="T3">table 3</xref>.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Summary of statements and recommendations</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" valign="bottom">Drug</th><th colspan="1" rowspan="1" valign="bottom">Statement</th><th colspan="1" rowspan="1" valign="bottom">Recommendation</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="top">DHE</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV DHE decreases headache frequency and severity in inpatients with CM, status migrainosus cluster headache and/or MOH.</p><p>Level of certainty: moderate</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Preinfusion ECG and hemodynamic monitoring before, during and after the infusion. Grade B</p></list-item><list-item><p>Consider IV DHE in select inpatients without significant vascular disease. Grade C</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Magnesium</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV Magnesium sulfate may improve migraine severity and associated symptoms with better tolerability than sumatriptan and prochlorperazine.</p><p>Level of certainty: low</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Administer 1–2 g of IV magnesium sulfate infused over 15 min in inpatients with migraine. Grade: I</p></list-item><list-item><p>Check pre-infusion magnesium levels and blood pressure, to rule out hypotension. Grade C</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Valproic Acid</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV VPA may be beneficial for inpatients with intractable migraine.</p><p>Level of certainty: low</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Consider IV VPA for intractable migraine in select inpatients. Grade C</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Ketorolac</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV ketorolac may be an effective and safe treatment option for managing acute migraine or non-NSAID MOH in the inpatient setting.</p><p>Level of certainty: Low</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Consider IV ketorolac for select inpatients with acute migraine or non-NSAID MOH. Grade C.</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Steroids</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV steroids may be useful in the inpatient treatment of status migrainosus, MOH, and trigeminal autonomic cephalalgias (TAC). Level of certainty: Moderate</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Consider IV dexamethasone or methylprednisolone for 1–3 days in selected inpatients with refractory CM with MOH, status migrainosus, and TACs including CH and HC. Grade C</p></list-item><list-item><p>Use GI prophylaxis. Steroids should be used with caution in patients with gastritis. Patients with diabetes mellitus should have blood glucose levels monitored and appropriately treated. Concurrent use of NSAIDs with steroids should be avoided. Grade B</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Levetiracetam</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV levetiracetam may be effective and safe to use in the acute management of intractable migraine or status migrainosus under specific circumstances. Level of certainty: Low</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Consider IV levetiracetam for inpatient management of acute migraine, when other therapies have been exhausted. Grade C</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Dopamine antagonists</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV dopamine antagonists may be effective in the acute treatment of intractable headaches in the inpatient setting.</p><p>Level of certainty: moderate</p></list-item><list-item><p>Side-effects of IV dopamine antagonists can be minimized with slow infusion.</p><p>Level of certainty: moderate</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV dopamine antagonists should be offered in the acute treatment of inpatients with intractable headaches. Grade B.</p></list-item><list-item><p>Home medications should be reviewed for drug interactions resulting in QTc prolongation. Obtain an ECG before using dopamine antagonists. Grade C</p></list-item><list-item><p>Slow rate of infusion over the course of 15 min to minimize the extrapyramidal symptoms. Grade B</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Lidocaine</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>IV lidocaine infusion may offer benefit for inpatients with TACs and intractable migraine and may be associated with mild AEs.</p><p>Level of certainty: low</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Duration of IV lidocaine should not routinely exceed 5 days to reduce risks associated with accumulation of a toxic metabolite. If prolonged infusion is warranted, then daily measurement of serum lidocaine levels may be considered. Grade C</p></list-item></list>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Ketamine</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Ketamine infusions may provide benefit in the acute treatment of intractable headache.</p><p>Level of certainty: low</p></list-item><list-item><p>Adverse effects can occur even at subanesthetic doses<bold>.</bold></p><p>Level of certainty: high</p></list-item><list-item><p>The incidence and severity of psychotomimetic and sympathomimetic effects from ketamine may be reduced by administration of clonidine or benzodiazepines.</p><p>Level of certainty: moderate</p></list-item></list>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<list list-content="ul" list-type="bullet"><list-item><p>Consider Ketamine infusions in the acute inpatient treatment of refractory headache. Grade C.</p></list-item><list-item><p>Ketamine infusion rates should not exceed 1 mg/kg/hour outside of intensive care unit settings. Grade B.</p></list-item><list-item><p>Continuous respiratory and hemodynamic monitoring while receiving ketamine infusions. Grade B.</p></list-item><list-item><p>Consider administering clonidine and/or a low-dose benzodiazepine to mitigate psychotomimetic and sympathomimetic adverse effects. Grade C</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>AEs, adverse events; CM, chronic migraine; DHE, dihydroergotamine; HC, hemicrania continua; IV, intravenous; MOH, medication overuse headache; NSAID, non-steroidal anti-inflammatory drug; VPA, valproate.</p></fn></table-wrap-foot></table-wrap><sec id="s3-1"><title>What is the evidence for the use of intravenous dihydroergotamine for inpatient headache management?</title><sec id="s3-1-1"><title>Mechanism of action</title><p>Dihydroergotamine (DHE) is a semisynthetic derivative of ergotamine, synthesized by Stoll and Hofmann in 1943.<xref ref-type="bibr" rid="R1"><sup>1 14</sup></xref> It has an affinity for serotonin, dopamine, and adrenergic receptors, with its antimigraine effect thought to be exerted through 5HT1B/5HT1D receptor activity.<xref ref-type="bibr" rid="R15"><sup>15 16</sup></xref> In addition, DHE seems to inhibit trigeminal pain processing in the brainstem and neurogenic inflammation in the trigeminovascular system.<xref ref-type="bibr" rid="R17"><sup>17 18</sup></xref> DHE is frequently used by headache practitioners due to its higher bioavailability and more favorable side effect profile in comparison to its predecessor (ergotamine) with less arterial vasoconstriction, lower likelihood of medication overuse headache (MOH), and lack of retroperitoneal fibrosis.<xref ref-type="bibr" rid="R19"><sup>19</sup></xref></p></sec><sec id="s3-1-2"><title>Study findings</title><p>Our systematic literature search yielded 15 retrospective observational studies (n=1213) on the use of intravenous DHE infusions in the setting of inpatient headache management. All studies were open-label studies of variable quality. No ED studies were included. The target population was generally primary headache syndromes with possible MOH. There was significant heterogeneity across studies in terms of headache type. Chronic daily headache (CDH) comprised the largest group with over 500 patients studied.<xref ref-type="bibr" rid="R20">20</xref><xref ref-type="bibr" rid="R22">22</xref> CDH, including chronic migraine (CM), hemicrania continua (HC), and new daily persistent headache (NDPH), is currently no longer used terminology for these headache disorders.</p><p>The overwhelming headache subtype was CM, comprised 269 patients.<xref ref-type="bibr" rid="R2">223</xref><xref ref-type="bibr" rid="R25">25</xref> Older studies used evolving terminology including transformed migraine (n=37), drug rebound headache (n=71), and chronic intractable headache.<xref ref-type="bibr" rid="R22"><sup>22 26 27</sup></xref> Other diagnoses included in studies were NDPH and cluster headache (CH), both episodic and chronic,<xref ref-type="bibr" rid="R2"><sup>2 20 25 26 28</sup></xref> and one study investigating short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache with autonomic symptoms (SUNA) in patients with coexisting chronic cluster or CM and tension-type headache.<xref ref-type="bibr" rid="R29"><sup>29</sup></xref> Across studies, heterogeneity in terms of duration of pain was noted, ranging from months to years.</p><p>Repetitive intravenous DHE was first evaluated in a study by Raskin.<xref ref-type="bibr" rid="R27"><sup>27</sup></xref> 55 patients with chronic intractable headache were treated with intravenous DHE and metoclopramide every 8 hours, whereas an age-matched and sex-matched control group received intravenous diazepam every 8 hours. 49 of the 55 DHE patients became headache-free within 48 hours, and 39 of them had sustained benefit at mean follow-up time of 16 months. In contrast, in the intravenous diazepam-treated group, only seven patients became headache-free within 3–6 days. The main critique of this study is that the outcomes are not representative of intravenous DHE use alone. All DHE patients were given metoclopramide, which has also been shown to be effective for migraine. Entry into the study required cessation of overused medications, and patients were placed on a regimen of propranolol and ergotamine in addition to DHE suppositories at posthospital discharge.<xref ref-type="bibr" rid="R30">30</xref><xref ref-type="bibr" rid="R32">32</xref></p><p>Subsequent case series have concluded that intravenous DHE is effective for CM, CDH, and CH. Most studies looked at pain relief during the allotted time of hospitalization, typically at 2–3 days.<xref ref-type="bibr" rid="R22">2224 27</xref><xref ref-type="bibr" rid="R30">30</xref> Other studies looked at headache improvement during the hospitalization without a fixed endpoint.<xref ref-type="bibr" rid="R2"><sup>2 20 25</sup></xref> Five studies<xref ref-type="bibr" rid="R21">2125</xref><xref ref-type="bibr" rid="R28">28</xref> offered long-term follow-up, and two studies<xref ref-type="bibr" rid="R21"><sup>21 25</sup></xref> examined functional metrics suggesting improvement in work absences, activity levels, and quality of life. It is important to note, however, that these studies were not a clear comparison of DHE to placebo. Rather, these studies investigated a regimen that involved cessation of previous medications that could trigger a rebound headache, commonly referred to as MOH today.<xref ref-type="bibr" rid="R21"><sup>21 24 26 27</sup></xref></p><p>Concurrent medications during the intravenous treatment included metoclopramide and often ended with the transition onto a new or different preventive medication.<xref ref-type="bibr" rid="R2"><sup>2 20 21 25 27</sup></xref> Results from NDPH suggested a lack of benefit<xref ref-type="bibr" rid="R25"><sup>25</sup></xref> or less robust results as compared with migraine,<xref ref-type="bibr" rid="R2"><sup>2</sup></xref> although the sample size was much smaller. DHE was ineffective for SUNCT and SUNA and made the condition worse in some patients.<xref ref-type="bibr" rid="R29"><sup>29</sup></xref></p><p>Both continuous and repetitive intravenous DHE dosing were used in the included studies, and both were shown to be effective.<xref ref-type="bibr" rid="R22"><sup>22</sup></xref> The continuous regimen is 3 mg of DHE in 1 L of normal saline administered at 42 mL/hour in an intravenous infusion pump over 24 hours, with 10 mg of intravenous metoclopramide given every 8 hours as needed. The dose can be lowered for problematic side effects and is decreased as the headache subsides. The dosing of repetitive DHE did differ in the literature from the standard ‘Raskin Protocol’ (0.5 mg every 8 hours with 10 mg of intravenous metoclopramide given pro re nata prior to each DHE infusion). This protocol was initially intended to run for seven doses (including an initial dose that is broken up into two parts for assessment of tolerability).<xref ref-type="bibr" rid="R27"><sup>27</sup></xref> However, this has gradually changed over the years and evolved into 9 doses,<xref ref-type="bibr" rid="R23"><sup>23</sup></xref> or 10 doses,<xref ref-type="bibr" rid="R29"><sup>29</sup></xref> or until headache improvement with taper when headache is abated.<xref ref-type="bibr" rid="R2"><sup>2 20 25 28</sup></xref> Interestingly, a study by Pringsheim and Howse dosed DHE 4 times in 24 hours for an unclear duration.<xref ref-type="bibr" rid="R21"><sup>21</sup></xref></p></sec><sec id="s3-1-3"><title>Adverse events</title><p>The most common side effects in the included studies were nausea and vomiting. Other reported side effects included leg cramps and diarrhea.<xref ref-type="bibr" rid="R2">220</xref><xref ref-type="bibr" rid="R28">23 27 28</xref> Transient headache exacerbation was also reported with DHE infusions.<xref ref-type="bibr" rid="R33"><sup>33</sup></xref> However, this is not a reason to stop infusions, as a 2016 study showed that headache exacerbation was not an independent predictor of treatment outcome via a multivariate logistic regression model.<xref ref-type="bibr" rid="R34"><sup>34</sup></xref> Vasospastic adverse events (AEs) are rare but possible; hence, DHE is contraindicated in patients with cardiac, cerebral or peripheral vascular disease or uncontrolled hypertension. A low threshold should be used when considering screening for catheter-associated venous thrombosis as DHE may increase its risk.<xref ref-type="bibr" rid="R35"><sup>35</sup></xref> DHE is also contraindicated in pregnancy, hemiplegic migraine, and migraine with brain stem aura.</p><p>In summary, based on expert opinion, it appears that intravenous DHE given in hospital, either via repetitive or continuous dosing, is relatively safe and tolerated. DHE frequently improves headache frequency and severity, in conjunction with a protocol to minimize MOH and implement migraine or CH prevention. Overall, the committee would recommend offering it to a select patient population depending on the individual circumstances.</p></sec><sec id="s3-1-4"><title>Statement</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous DHE decreases headache frequency and severity in inpatients with CM, status migrainosus CH and/or MOH. Level of certainty: moderate</p></list-item></list></sec><sec id="s3-1-5"><title>Recommendations</title><list list-content="ul" list-type="bullet"><list-item><p>Based on vasospastic AEs, the committee recommends preinfusion ECG and hemodynamic monitoring (blood pressure and heart rate) before, during, and after the infusion. Grade B.</p></list-item></list><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends offering intravenous DHE in select inpatients without significant vascular disease being treated for status migrainosus. Grade C.</p></list-item></list></sec></sec><sec id="s3-2"><title>What is the evidence for the use of intravenous magnesium sulfate for inpatient headache management?</title><sec id="s3-2-1"><title>Mechanism of action</title><p>Magnesium has multiple roles in the central and peripheral nervous systems, including reducing cortical hyperexcitability, partly due to modulating N-methyl-D-aspartate (NMDA) sensitivity, modulating neurotransmission, and regulating vascular tone, all involved in migraine pathophysiology.<xref ref-type="bibr" rid="R36"><sup>36</sup></xref> Patients with migraine demonstrate lower plasma and brain intracellular magnesium levels compared with controls.<xref ref-type="bibr" rid="R37"><sup>37 38</sup></xref></p></sec><sec id="s3-2-2"><title>Study findings</title><p>At the time of writing, no randomized controlled trials (RCTs) or observational studies assessed intravenous magnesium for the treatment of patients admitted with headache. Studies that included ED patients were included because of a lack of inpatient studies.</p><p>One gram of intravenous magnesium sulfate administered over 15 min was superior to placebo in migraine pain relief, pain freedom, and freedom from other migraine-associated symptoms, including photophobia, phonophobia, and nausea.<xref ref-type="bibr" rid="R39"><sup>39</sup></xref> Magnesium sulfate infusion was superior to dexamethasone/metoclopramide in pain severity reduction at 20 min, 1 hour, and 2 hours postinfusion.<xref ref-type="bibr" rid="R40"><sup>40</sup></xref> Two grams of intravenous magnesium sulfate demonstrated similar effectiveness to sumatriptan, metoclopramide, and prochlorperazine.<xref ref-type="bibr" rid="R41"><sup>41 42</sup></xref></p><p>Patients with low ionized magnesium serum levels (&lt;0.54 mmol/L) demonstrated longer-lasting migraine pain relief than patients with normal levels.<xref ref-type="bibr" rid="R43"><sup>43</sup></xref> In a few studies, only patients with migraine with aura showed a significantly greater reduction in pain and other migraine-associated symptoms with magnesium sulfate compared with controls.<xref ref-type="bibr" rid="R36">3644</xref><xref ref-type="bibr" rid="R46">46</xref> Another double-blind RCT of intravenous magnesium sulfate versus placebo (normal saline) revealed significant improvement in migraine pain and nausea in patients with migraine with aura. Pain improvement (although not statistically significant) was found among patients with migraine without aura, with a significant improvement in photo and phonophobia.<xref ref-type="bibr" rid="R47"><sup>47</sup></xref> Two case reports demonstrated clinical improvement within 24 hours in patients with prolonged status migrainous aura/hemiplegic migraine with prochlorperazine and 1 g of intravenous magnesium sulfate given every 12 hours.<xref ref-type="bibr" rid="R48"><sup>48</sup></xref></p><p>The most common dose was 1–2 g of intravenous magnesium sulfate infused over 15 min. There are conflicting data regarding adjuvant therapy, with a study demonstrating the added benefit of combining magnesium sulfate with metoclopramide.<xref ref-type="bibr" rid="R49"><sup>49</sup></xref> In contrast, another study suggested that adding magnesium sulfate attenuated the effectiveness of metoclopramide.<xref ref-type="bibr" rid="R45"><sup>45</sup></xref> Other studies have combined magnesium sulfate with 10 mg of prochlorperazine and meperidine as a rescue medication.<xref ref-type="bibr" rid="R36"><sup>36 48</sup></xref></p></sec><sec id="s3-2-3"><title>Adverse events</title><p>Intravenous magnesium sulfate was better tolerated than sumatriptan and prochlorperazine, with the most common side effects including sensation of warmth at the intravenous infusion site, flushing, mild burning sensation in the face and neck, and asymptomatic drop in systolic blood pressure.<xref ref-type="bibr" rid="R41"><sup>41 42</sup></xref> Repeated doses can be administered daily. Hemodynamic monitoring is recommended due to the potential for hypotension with rapid infusion due to smooth muscle relaxation. Magnesium should be avoided in patients with neuromuscular disease, heart block, or previous hypersensitivity. We recommend serum levels be tracked in these patients to avoid hypermagnesemia.</p><p>In summary, we extrapolated our recommendations primarily from studies that included ED patients. Based on evidence from ED literature, the committee recommends 1–2 g of intravenous magnesium sulfate infused over 15 min in inpatients with migraine (with or without aura), without hypermagnesemia and without a history of hypersensitivity, neuromuscular disease, or heart block. It is recommended to perform hemodynamic monitoring and to check magnesium levels prior to daily infusions.</p></sec><sec id="s3-2-4"><title>Statement</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous magnesium sulfate may improve migraine severity and associated symptoms in inpatients, with better tolerability than sumatriptan and prochlorperazine. Level of certainty: low</p></list-item></list></sec><sec id="s3-2-5"><title>Recommendations</title><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends using 1–2 g of intravenous magnesium sulfate infused over 15 min in inpatients with migraine (with or without aura). Grade: I.</p></list-item></list><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends checking preinfusion magnesium levels and blood pressure to rule out hypotension. Grade C.</p></list-item></list></sec></sec><sec id="s3-3"><title>What is the evidence for the use of intravenous valproate sodium for inpatient headache management?</title><sec id="s3-3-1"><title>Mechanism of action</title><p>Valproate sodium (VPA) is an intravenous injection approved by the US Food and Drug Administration for seizure management. In contrast, divalproex sodium is an oral formula indicated for managing not only seizures, but also bipolar disorder and migraine. VPA has multiple mechanisms of action, including potentiation of γ-aminobutyric acid and blockade of sodium channels, NMDA-mediated excitation, and T-type calcium channels.</p><p>Importantly, VPA use is contraindicated in several conditions, including migraine prevention during pregnancy due to the risk of neural tube defects.<xref ref-type="bibr" rid="R50"><sup>50</sup></xref></p></sec><sec id="s3-3-2"><title>Study findings</title><p>The American Headache Society (AHS) endorsed oral divalproex sodium use with established efficacy for migraine prevention,<xref ref-type="bibr" rid="R51"><sup>51</sup></xref> whereas intravenous VPA may be offered to adults with acute migraine in the ED (Level C).<xref ref-type="bibr" rid="R52"><sup>52</sup></xref> A recent meta-analysis on the single use of intravenous VPA in the ED, including 7 double-blinded RCTs of 682 patients, noted inferiority in effectiveness relative to other treatments (eg, metoclopramide, ketorolac, prochlorperazine) for acute migraine, but similarity to dexamethasone for status migrainosus.<xref ref-type="bibr" rid="R53"><sup>53</sup></xref> A more recent RCT reported the superiority of intravenous VPA over intravenous ibuprofen in the ED.<xref ref-type="bibr" rid="R54"><sup>54</sup></xref> In the clinic setting, 400 mg of intravenous VPA was as effective as 6 mg of subcutaneous sumatriptan in a double-blinded RCT.<xref ref-type="bibr" rid="R55"><sup>55</sup></xref> In an open-label randomized study, 500 mg of intravenous VPA was similarly effective to 10 mg of intramuscular metoclopramide with 1 mg of DHE.<xref ref-type="bibr" rid="R56"><sup>56</sup></xref> In another open-label observational study, 75% of migraine patients reported pain relief in 60 min on 900–1200 mg of intravenous VPA.<xref ref-type="bibr" rid="R57"><sup>57</sup></xref> While single-dose intravenous VPA appeared somewhat effective for acute migraine use, repetitive intravenous VPA use in the inpatient setting has not been properly studied.</p><p>At the time of writing, no RCTs or prospective observational studies have examined the role of repetitive intravenous VPA for inpatient headache management. We found two small low-quality case series (n=24) which reported on the use of intravenous VPA in patients admitted briefly to hospitals.<xref ref-type="bibr" rid="R58"><sup>58 59</sup></xref> No ED studies were included. Schwartz <italic toggle="yes">et al</italic> studied 10 patients with CDH or transformed migraine and/or MOH, who received a 15 mg/kg loading dose of intravenous VPA infused over 30 min, followed by 5 mg/kg infused every 8 hours for 4.3 days on average.<xref ref-type="bibr" rid="R58"><sup>58</sup></xref> Eight patients had headache improvement, with four having total or near-total headache resolution. There were minimal AEs, with one patient having dysarthria, dysmetria, and nystagmus resulting in a 25% dose reduction. Notably, patients also had their preventive medications adjusted and were taught how to avoid MOH with the correct use of acute medications.</p><p>Riggins <italic toggle="yes">et al</italic> retrospectively reported on 14 patients with CM.<xref ref-type="bibr" rid="R59"><sup>59</sup></xref> Over 4-day of treatment, patients received 250 mg of intravenous VPA infusions over 60 min, repeated every 8 hours, with a total dose ranging from 1125 to 2250 mg. They noted that 69% had improvement in their headache frequency, intensity, and/or use of acute medications 4–6 weeks following admission. One patient had to discontinue the protocol due to nausea/vomiting and vertigo, and another patient had restlessness/anxiety that improved by prolonging the infusion to 120 min.</p><p>We found a retrospective study (n=160) on the pharmacokinetics of intravenous VPA in pediatric and adult patients admitted to hospital (most commonly for seizures and migraine).<xref ref-type="bibr" rid="R60"><sup>60</sup></xref> This study identified 160 adult migraine patients who received intravenous VPA (loading dose of 20–40 mg/kg over 30–60 min, followed by a continuous infusion of 1 mg/kg/hour with a target concentration of 50–100 µg/mL). They reported that 63.3% of patients had a &gt;50% reduction in pain score, with the remaining 36.7% having &lt;30% reduction in pain score (no patients were categorized as having a 30%–50% reduction in pain score).</p></sec><sec id="s3-3-3"><title>Adverse events</title><p>Common AEs included gastrointestinal (GI) complaints (7.3%), hyperammonemia (3.6%), elevated liver enzymes &gt;3 times the upper limit of normal (1.2%), and platelets &lt;1x10ˆ5/cc (1.8%). It is worth noting that while the maximal tolerated dose of intravenous VPA is 140 mg/kg in healthy volunteers, intravenous VPA-related drug interactions (eg, metabolic inhibitions, displacement of protein binding sites) may lead to serious drug toxicity, especially under higher intravenous VPA dosage.<xref ref-type="bibr" rid="R61"><sup>61</sup></xref></p><p>In summary, the available evidence for repetitive intravenous VPA in managing inpatient headache is limited. Although it has been used for managing CDH or CM, its optimal dosing regimen has not been determined. Nevertheless, intravenous VPA may be a consideration for the management of inpatient headache depending on individual patient and contextual factors.</p></sec><sec id="s3-3-4"><title>Statement</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous VPA may be beneficial for inpatients with intractable migraine. Level of certainty: low Recommendation:</p></list-item></list><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends offering intravenous VPA for intractable migraine in select inpatients. Grade C.</p></list-item></list></sec></sec><sec id="s3-4"><title>What is the evidence for the use of intravenous ketorolac for inpatient headache management?</title><sec id="s3-4-1"><title>Mechanism of action</title><p>Ketorolac is a potent analgesic non-steroidal anti-inflammatory drug (NSAID) used for treating migraine. Its mechanism of action involves the inhibition of spinal cyclooxygenase activity, which is responsible for prostaglandin biosynthesis. This inhibitory effect terminates migraines associated with central sensitization and allodynia.<xref ref-type="bibr" rid="R62"><sup>62</sup></xref> Studies have also shown that ketorolac can reduce mast cell degranulation and block dural macrophage activation.<xref ref-type="bibr" rid="R63"><sup>63 64</sup></xref> Richer <italic toggle="yes">et al</italic> found that ketorolac effectively reduced central sensitization in animal models of migraine and in adult subjects, highlighting its potential as a treatment option.<xref ref-type="bibr" rid="R65"><sup>65</sup></xref> Intramuscular or intravenous ketorolac exhibits a rapid onset of action, with effects achieved within 10 min and peak effect reached after 75–150 min.<xref ref-type="bibr" rid="R66"><sup>66</sup></xref></p></sec><sec id="s3-4-2"><title>Study findings</title><p>Our literature search did not find any studies on the use of ketorolac for the inpatient setting. Studies that included ED patients were included because of lack of inpatient studies. Intravenous ketorolac has been studied for the treatment of migraine in the ED. When compared with other parenteral drugs, such as VPA and prochlorperazine, intravenous ketorolac was found to be effective in this setting.<xref ref-type="bibr" rid="R67">67</xref><xref ref-type="bibr" rid="R69">69</xref></p></sec><sec id="s3-4-3"><title>Adverse events</title><p>The administration of ketorolac may be associated with GI bleeding, nephropathies, hematological dysfunction, and increased risk of cardiovascular events, including thrombotic events, myocardial infarction, stroke, and heart failure, and should be avoided in patients with or at high risk for the aforementioned conditions. Dosage adjustment and short-term uses can help minimize these severe events.<xref ref-type="bibr" rid="R70">70</xref><xref ref-type="bibr" rid="R72">72</xref> Other possible side effects may include dizziness, nausea, or vomiting, which are typically of mild intensity and tolerable in patients.<xref ref-type="bibr" rid="R70"><sup>70</sup></xref></p><p>The utility of ketorolac is its ease of use, as it does not require hemodynamic monitoring or other specialized monitoring. For patients less than 65 years old, and provided no GI, renal, or cardiovascular contraindications, intravenous ketorolac is dosed at 10–30 mg once every 6–8 hours. The total time for therapy with ketorolac is not to exceed 5 days for risk mitigation.<xref ref-type="bibr" rid="R72"><sup>72</sup></xref> While 30 mg is an often-used dose, the analgesic effect of intravenous ketorolac exhibits a ceiling effect at 10 mg. Using lower doses is thus effective and may further reduce adverse effects.<xref ref-type="bibr" rid="R73"><sup>73</sup></xref></p><p>In summary, there are no published studies on intravenous ketorolac use for migraine and MOH in non-ED inpatient settings. Notably, the AHS has rated ketorolac as probably effective for acute migraine management in the ED.<xref ref-type="bibr" rid="R52"><sup>52 74</sup></xref> More studies are needed to validate the effectiveness of ketorolac for the management of migraine in the inpatient setting. From extrapolation of ED studies, there is a consensus among medical experts that intravenous ketorolac could be an effective treatment option for managing acute migraine and NSAID MOH in inpatient settings.</p></sec><sec id="s3-4-4"><title>Statement</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous ketorolac may be an effective and safe treatment option for managing acute migraine and non-NSAID MOH in the inpatient setting. Level of certainty: Low</p></list-item></list></sec><sec id="s3-4-5"><title>Recommendation</title><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends offering intravenous ketorolac for select inpatients with acute migraine or non-NSAID MOH. Grade C.</p></list-item></list></sec></sec><sec id="s3-5"><title>What is the evidence for the use of intravenous steroids for inpatient headache management?</title><sec id="s3-5-1"><title>Mechanism of action</title><p>Systemic corticosteroids have a long history in headache management as monotherapy or adjunctive. The main analgesic mechanisms of corticosteroids include decreased inflammation due to inhibition of prostaglandin synthesis, reduced vascular permeability and tissue edema, suppression of stress responses in the hypothalamic–pituitary axis, and modulation of neuroplasticity.<xref ref-type="bibr" rid="R75"><sup>75</sup></xref> Administration of steroids for headache management is typically limited to short duration due to the well-known systemic side effects of long-term corticosteroid use, including Cushing syndrome, immunosuppression, neuropsychiatric dysfunction, osteoporosis, and GI bleeding.<xref ref-type="bibr" rid="R76"><sup>76</sup></xref> Simultaneous use of corticosteroids with NSAIDs should be avoided due to increased risk of gastritis and GI bleed.</p></sec><sec id="s3-5-2"><title>Study findings</title><p>The European Federation of Neurological Societies (EFNS) migraine treatment guideline recommends use of corticosteroids for status migrainosus by expert consensus, acknowledging that the data from RCTs are mixed regarding effectiveness in acute migraine treatment and recurrence prevention.<xref ref-type="bibr" rid="R77"><sup>77</sup></xref> Similarly, the AHS assessed 4–16 mg of intravenous dexamethasone for acute migraine treatment as level C (possibly effective or ineffective).<xref ref-type="bibr" rid="R74"><sup>74</sup></xref> Both the European Academy of Neurology and EFNS guidelines for CH concluded that corticosteroids are effective for CH prevention, based primarily on data from open-label studies and clinical experience, although this also includes oral and locally injected steroid.<xref ref-type="bibr" rid="R78"><sup>78 79</sup></xref> The overwhelming majority of evidence from RCTs supporting the above guidelines was performed in the outpatient or ED setting.</p><p>Focusing specifically on inpatient headache management, nine papers on intravenous steroids met criteria for inclusion; three case reports, three case series, two observational studies, and a preliminary report from an RCT (n=141). No ED studies were included. The preliminary report from the RCT<xref ref-type="bibr" rid="R80"><sup>80</sup></xref> and both observational studies<xref ref-type="bibr" rid="R81"><sup>81 82</sup></xref> assessed MOH. We found three case reports<xref ref-type="bibr" rid="R83">83</xref><xref ref-type="bibr" rid="R85">85</xref> investigating the use of intravenous steroids for patients with SUNCT, two case series<xref ref-type="bibr" rid="R86"><sup>86 87</sup></xref> for CH management, and one case series<xref ref-type="bibr" rid="R88"><sup>88</sup></xref> for HC.</p><p>For MOH, preliminary results of the multicenter RCT reported on the first 23 patients enrolled at 2 of 10 planned Italian centers.<xref ref-type="bibr" rid="R80"><sup>80</sup></xref> The patients were randomized to receive either 125 mg of methylprednisolone plus 10 mg of diazepam (14 patients) or 10 mg of diazepam alone (9 patients). A significant decrease was observed in the whole sample (p=0.005), but no significant difference in effectiveness was observed between the treatment groups, likely due to the small sample size (p=0.76). Both cohort studies were also performed in Italy, using multimodal treatment regimens lasting 7–10 days including intravenous anxiolysis (eg, daily diazepam), prophylactic medications (eg, amitriptyline, topiramate), and 4 mg<xref ref-type="bibr" rid="R83"><sup>83</sup></xref> or 8 mg<xref ref-type="bibr" rid="R81"><sup>81</sup></xref> of intravenous dexamethasone daily.</p><p>At 1 month, 26 out of 32 patients (81%) in one study<xref ref-type="bibr" rid="R81"><sup>81</sup></xref> and 46 out of 52 patients (89%) in the other study<xref ref-type="bibr" rid="R82"><sup>82</sup></xref> no longer had medication overuse, although these rates decreased substantially in long-term follow-up (45% at 6 months).<xref ref-type="bibr" rid="R81"><sup>81</sup></xref></p><p>In all three cases of intravenous steroids for SUNCT, patients were administered 1 g of intravenous methylprednisolone for 3 days, in conjunction with other medications for headache prophylaxis, most notably membrane stabilizers such as carbamazepine<xref ref-type="bibr" rid="R83"><sup>83 85</sup></xref> or topiramate.<xref ref-type="bibr" rid="R84"><sup>84</sup></xref> Similarly, the two case series for refractory CH used 1 g intravenous methylprednisolone for 3 days<xref ref-type="bibr" rid="R87"><sup>87</sup></xref> or 125–500 mg for 2–3 days.<xref ref-type="bibr" rid="R86"><sup>86</sup></xref> The two patients in the HC case series received repeated infusions of 500 mg of intravenous methylprednisolone for 1–3 days, with complete headache response.<xref ref-type="bibr" rid="R88"><sup>88</sup></xref> Long-term remission was reported in all cases.</p></sec><sec id="s3-5-3"><title>Adverse events</title><p>Three reports specifically stated no apparent adverse effects;<xref ref-type="bibr" rid="R86">86</xref><xref ref-type="bibr" rid="R88">88</xref> the remaining cases did not comment on AEs.</p><p>In summary, there is limited evidence on the effectiveness of intravenous steroids in the inpatient treatment of acute headache and some evidence for their effectiveness in the prevention of headache recurrence.</p></sec><sec id="s3-5-4"><title>Statement</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous steroids may be useful in the inpatient treatment of status migrainosus, MOH, and trigeminal autonomic cephalalgias (TACs). Level of certainty: Moderate</p></list-item></list></sec><sec id="s3-5-5"><title>Recommendations</title><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends using intravenous dexamethasone or intravenous methylprednisolone for 1–3 days in selected inpatients with refractory CM with MOH, status migrainosus, and TACs including CH and HC. Grade C</p></list-item></list><p>In patients who are administered intravenous steroids for inpatient headache, the committee recommends use of GI prophylaxis. Steroids should be used with caution in patients with gastritis, and patients with diabetes mellitus should have blood glucose levels monitored and appropriately treated until glucose levels return to baseline. Concurrent use of NSAIDs with steroids should be avoided. Grade B</p></sec></sec><sec id="s3-6"><title>What is the evidence for the use of intravenous levetiracetam for inpatient headache management?</title><sec id="s3-6-1"><title>Mechanism of action</title><p>Levetiracetam is a broad-spectrum antiepileptic medication against various seizure types and used as a second-line agent in the treatment of status epilepticus.<xref ref-type="bibr" rid="R89"><sup>89 90</sup></xref> Known for its effectiveness and good tolerability, levetiracetam operates through a unique mechanism by interacting with the synaptic vesicle protein 2A. Its actions extend to calcium homeostasis, GABA-ergic system modulation, and targeting α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, contributing to its antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties.<xref ref-type="bibr" rid="R91"><sup>91</sup></xref></p><p>Levetiracetam has a favorable pharmacokinetic profile with rapid and complete absorption following oral administration, excellent bioavailability, quick achievement of steady state concentrations, linear kinetics, and minimal plasma protein binding.<xref ref-type="bibr" rid="R92"><sup>92</sup></xref> It has no hepatic metabolism and is renally excreted in the form of inactive metabolites. This makes it a preferred option for patients with hepatic disease, but caution is advised in those with renal impairment.<xref ref-type="bibr" rid="R93"><sup>93</sup></xref></p></sec><sec id="s3-6-2"><title>Study findings</title><p>As of now, there are no publications specifically addressing the inpatient management of migraine with intravenous levetiracetam. The existing evidence primarily relies on a case report and a small open-label study that investigated intravenous levetiracetam use in ED and outpatient settings.</p><p>A case report documented a positive outcome in treating status migrainosus in the ED with a single dose of 1000 mg levetiracetam infusion in a patient with a history of migraine with aura and complex partial epilepsy.<xref ref-type="bibr" rid="R94"><sup>94</sup></xref> In an open-label study focusing on outpatient intravenous levetiracetam treatment for acute intractable migraine, half of the patients achieved complete migraine resolution, with an average decrease in severity of 77.2%. The administered dose was 400 mg of intravenous levetiracetam every 5 min, up to a maximum effect, resulting in an average total dose of 4167 mg (range 400–11200 mg) over 56 min.<xref ref-type="bibr" rid="R95"><sup>95</sup></xref></p><p>A proposed approach to ED and inpatient headache management in adults suggested the use of intravenous levetiracetam at a dose of 500–1500 mg as a second-line option, particularly for patients experiencing migraine aura status or prolonged aura.<xref ref-type="bibr" rid="R4"><sup>4</sup></xref> This recommendation is based on results from a small open-label study of 1000 mg oral levetiracetam treatment over 6 months in high-frequency migraine with aura, resulting in significant reductions in headache severity, duration, and aura symptoms.<xref ref-type="bibr" rid="R96"><sup>96</sup></xref></p><p>Indirect evidence supporting the effectiveness of levetiracetam in migraine comes from its impact as migraine preventive medication. SR and meta-analysis on the effectiveness of levetiracetam for migraine prevention demonstrated the effectiveness of oral levetiracetam in reducing headache frequency and severity for adults with episodic migraine. The achievement of a 50% reduction in frequency ranged from 57.9% to 100%, with levetiracetam dosages varying from 500 to 3000 mg per day. Notably, inconsistent results were observed in the preventive treatment of CM.<xref ref-type="bibr" rid="R97"><sup>97 98</sup></xref></p><p>The recent Canadian Headache Society guidelines give levetiracetam a weak recommendation with low quality of evidence for episodic migraine prevention and recommend against use for CM.<xref ref-type="bibr" rid="R99"><sup>99</sup></xref></p></sec><sec id="s3-6-3"><title>Adverse events</title><p>Importantly, levetiracetam exhibits no clinically significant pharmacokinetic interactions and presents with mild adverse effects. Intravenous administration aligns with the safety and pharmacokinetic properties established for the oral formulation.<xref ref-type="bibr" rid="R100"><sup>100</sup></xref> Common adverse effects of levetiracetam include somnolence, dizziness, and asthenia. While depression and anxiety are possible, psychosis is rare.<xref ref-type="bibr" rid="R89"><sup>89 92 93</sup></xref></p><p>In summary, while oral levetiracetam has demonstrated some evidence of effectiveness and safety as a preventive treatment for episodic migraine, the use of intravenous levetiracetam for migraine management in an inpatient setting is characterized by uncertainty and insufficient evidence. The current knowledge gap underscores the need for further research to provide a more comprehensive understanding of the potential benefits and risks of intravenous levetiracetam in this specific scenario. Based on extrapolation from ED studies, the committee recommends:</p></sec><sec id="s3-6-4"><title>Statement</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous levetiracetam may be effective and safe to use in the acute management of intractable migraine or status migrainosus under specific circumstances. Level of certainty: Low</p></list-item></list></sec><sec id="s3-6-5"><title>Recommendation</title><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends that intravenous levetiracetam may be considered for inpatient management of acute migraine, when other therapies have been exhausted. Grade C</p></list-item></list></sec></sec><sec id="s3-7"><title>What is the evidence for the use of intravenous dopamine antagonists for inpatient headache management?</title><sec id="s3-7-1"><title>Mechanism of action</title><p>Dopamine antagonists are often used for acute treatment of headache given their antiemetic, sedating, and headache-relieving effects. Patients with migraine have been shown to have higher peripheral dopamine receptor density, dopamine agonist hypersensitivity, and ictal dopamine surges that are correlated with pain severity, which suggests that those with classic dopamine-mediated symptoms (eg, premonitory yawning, nausea, and vomiting) may derive greater benefit. The central and analgesic effects of dopamine antagonists are less clear due to complex pathophysiology but are potentially related to actions on dopaminergic inhibition of the trigeminocervical complex via hypothalamic projections and effects on ictal dopamine release.<xref ref-type="bibr" rid="R101">101</xref><xref ref-type="bibr" rid="R104">104</xref></p><p>Examples of common dopamine antagonists used in headache management include metoclopramide, prochlorperazine, chlorpromazine, promethazine, haloperidol, and droperidol. SR by the AHS and American Academy of Neurology have provided guidance regarding infusion dosage on the most studied dopamine antagonists giving level B evidence (probably effective) for 12.5 mg of chlorpromazine, 10 mg of metoclopramide, and 10 mg of prochlorperazine.<xref ref-type="bibr" rid="R74"><sup>74 105</sup></xref></p></sec><sec id="s3-7-2"><title>Study findings</title><p>Limited evidence is present regarding the effectiveness of intravenous dopamine antagonists for inpatient headache management specifically: we found one RCT, one prospective and two retrospective observational studies (n=275). No ED studies were included. Most studied medications in this setting are metoclopramide, prochlorperazine, and chlorpromazine, which have been shown to reduce headache intensity prior to discharge. Dosing frequency included once daily, every 8–12 hours, and a single repeat dose after 1 hour.</p><p>In addition to metoclopramide,<xref ref-type="bibr" rid="R106"><sup>106</sup></xref> prochlorperazine,<xref ref-type="bibr" rid="R107"><sup>107</sup></xref> and chlorpromazine,<xref ref-type="bibr" rid="R108">108</xref><xref ref-type="bibr" rid="R111">111</xref> RCTs in the ED have assessed the effectiveness of intravenous droperidol, promethazine, and haloperidol for the acute treatment of headache. Similar effectiveness was observed with droperidol and promethazine when compared with prochlorperazine.<xref ref-type="bibr" rid="R112">112</xref><xref ref-type="bibr" rid="R114">114</xref> Haloperidol was shown to have improved outcomes when compared with placebo<xref ref-type="bibr" rid="R115"><sup>115</sup></xref> and similar outcomes to metoclopramide.<xref ref-type="bibr" rid="R116"><sup>116</sup></xref></p><p>When given as part of a multidrug regimen over the course of an admission, along with implementation of preventive treatment and counseling, the use of intravenous dopamine antagonists has shown reductions in headache frequency, analgesic use, and acute care utilization following hospital discharge.</p></sec><sec id="s3-7-3"><title>Adverse events</title><p>AEs with intravenous dopamine antagonists include sedation, hypotension, QTc prolongation,<xref ref-type="bibr" rid="R37"><sup>37</sup></xref> and extrapyramidal symptoms (akathisia or dystonic reactions), with some studies showing a reduction in extrapyramidal symptoms when infused at a slower rate over 15 min.<xref ref-type="bibr" rid="R117">117</xref><xref ref-type="bibr" rid="R122">122</xref></p><p>In summary, depending on patient and clinicians’ preferences, intravenous dopamine antagonists (metoclopramide, prochlorperazine, chlorpromazine, droperidol, or haloperidol) should be offered to patients admitted to the hospital for acute treatment of headache, with the best evidence supporting the use of prochlorperazine and metoclopramide. Extrapyramidal symptoms can be minimized with a slower rate of infusion over the course of 15 min, which may prevent the need for the use of further sedating antihistamine medications. Home medications should be reviewed for drug interactions resulting in QTc prolongation with concomitant use. An ECG should be obtained prior to the use of any dopamine antagonists. For droperidol, ECG monitoring should also be obtained until 2–3 hours after completing treatment</p></sec><sec id="s3-7-4"><title>Statements</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous dopamine antagonists may be effective in the acute treatment of intractable headaches in the inpatient setting. Level of certainty: moderate</p></list-item><list-item><p>Side effects of intravenous dopamine antagonists can be minimized with slow infusion. Level of certainty: moderate</p></list-item></list></sec><sec id="s3-7-5"><title>Recommendations</title><list list-content="ul" list-type="bullet"><list-item><p>The committee recommends that intravenous dopamine antagonists should be offered in the acute treatment of intractable headaches in the inpatient setting. Grade B.</p></list-item><list-item><p>The committee recommends that home medications should be reviewed for drug interactions resulting in QTc prolongation with concomitant use. An ECG should be obtained prior to the use of any dopamine antagonists. Grade C.</p></list-item></list><list list-content="ul" list-type="bullet"><list-item><p>To minimize the extrapyramidal symptoms, the committee recommends a slower rate of infusion over the course of 15 min. Grade B.</p></list-item></list></sec></sec><sec id="s3-8"><title>What is the evidence for the use of intravenous lidocaine for inpatient headache management?</title><sec id="s3-8-1"><title>Mechanism of action</title><p>Intravenous lidocaine has been demonstrated to be both safe and efficacious in various chronic pain disorders,<xref ref-type="bibr" rid="R123"><sup>123</sup></xref> but its study in CDH is more limited. Lidocaine is a sodium channel blocker, and its mechanism of action in the treatment of CDH has been suggested to be multifaceted, with mention of antinociceptive, anti-hyperalgesic, as well as anti-inflammatory effects playing a role in relieving symptoms.<xref ref-type="bibr" rid="R124"><sup>124</sup></xref></p></sec><sec id="s3-8-2"><title>Study findings</title><p>A systematic literature search yielded 13 papers (n=953). One non-RCT, seven observational studies, and five case reports/series, all addressing the effectiveness and safety of lidocaine for the treatment of CDH in the inpatient setting. No ED studies were included. The non-randomized open-label study examined the utility of intravenous lidocaine in patients with SUNCT or SUNA. The observational studies all examined migraine as the primary headache disorder,<xref ref-type="bibr" rid="R2">2123 125</xref><xref ref-type="bibr" rid="R128">128</xref> two of which also described patients with a subset of TAC.<xref ref-type="bibr" rid="R123"><sup>123 129</sup></xref> The case reports described intravenous lidocaine in SUNCT (6/8 cases),<xref ref-type="bibr" rid="R130">130</xref><xref ref-type="bibr" rid="R132">132</xref> HC<xref ref-type="bibr" rid="R133"><sup>133</sup></xref> and SUNA<xref ref-type="bibr" rid="R134"><sup>134</sup></xref> (one each) respectively. Most captured studies described a patient population that was disproportionately female<xref ref-type="bibr" rid="R123">123127</xref><xref ref-type="bibr" rid="R135">129 135</xref> with reported mean ages from 39 to 45. Of all included studies, only one observational study used a comparator arm in their design.</p><p>All studies investigating migraine were observational and used varying doses, duration of treatment, and follow-up intervals. While the majority of studies did not use a weight-based dosing protocol, doses ranged from 0.5 to 1.5 mg/kg/hour among studies that did incorporate weight into dosing.<xref ref-type="bibr" rid="R130"><sup>130 131 134</sup></xref> Non-weight-based regimens ranged from approximately 0.5–4.0 mg/min with most studies using between 1 and 2 mg/min.<xref ref-type="bibr" rid="R126">126</xref><xref ref-type="bibr" rid="R133">128130</xref></p><p>Based on the available evidence, intravenous lidocaine may be indicated for inpatient management of TACs and migraine. The single non-randomized open-label prospective study by Lambru <italic toggle="yes">et al</italic> found that 91% of patients (52/58) were responders (ie, &gt;50% benefit), with the vast majority of responders experiencing maximal benefit at infusion rates of 120 mg/hour.<xref ref-type="bibr" rid="R135"><sup>135</sup></xref> The mean duration of benefit was classified as 22.1 days, but half of the responders suffered from a recurrence of attacks immediately after termination of the infusion. Three patients discontinued the infusion due to side effects (cognitive slowing and paranoid thoughts).</p><p>Of the observational studies, only Schwenk <italic toggle="yes">et al</italic> examined outcomes beyond discharge,<xref ref-type="bibr" rid="R126"><sup>126 127</sup></xref> with one study demonstrating a sustained response rate of 43%<xref ref-type="bibr" rid="R126"><sup>126</sup></xref> at 1-month postdischarge, while the other demonstrated no sustained benefit.<xref ref-type="bibr" rid="R127"><sup>127</sup></xref> Many studies reported AEs, with the most reported ones being vomiting, hallucinations, agitation, and cardiovascular changes.</p><p>Several studies examined outcomes at hospital discharge. Kiarashi noted that 7 out of 11 patients reported improvement in headache symptoms, 1 reported worsening of symptoms, and 3 reported no change at discharge. Patients also received other intravenous medications during the infusion, thus potentially confounding the results.<xref ref-type="bibr" rid="R2"><sup>2</sup></xref></p><p>Ray <italic toggle="yes">et al</italic> reported 51% of patients achieving a 50% or greater reduction in pain after a mean lidocaine infusion of 4.5 days and 31% of patients achieving pain freedom with a mean lidocaine infusion duration of 6.2 days at discharge.<xref ref-type="bibr" rid="R128"><sup>128</sup></xref></p><p>Hand and Stark demonstrated lidocaine infusions were successful in alleviating headache symptoms with four infusions in three patients, whereas one infusion was deemed partially successful. Median response to achieve analgesia was 24 hours. While outcome measures were reported beyond the discharge period, the reported data did not clearly differentiate between varying headache diagnoses.<xref ref-type="bibr" rid="R125"><sup>125</sup></xref></p></sec><sec id="s3-8-3"><title>Adverse events</title><p>Most studies reported minor AEs including nausea, vomiting, cardiovascular issues, and blurry vision. Some AEs required temporary cessation of the lidocaine infusion until symptoms resolved. A few studies used continuous telemetry<xref ref-type="bibr" rid="R129"><sup>129 131 134</sup></xref>; however, some studies reported baseline ECG and intermittent monitoring.<xref ref-type="bibr" rid="R2"><sup>2 125</sup></xref></p><p>In summary, the literature suggests a dosing of 1–2 mg/min of intravenous lidocaine infusion in the inpatient setting, with an ideal dose range of 0.5 mg/min to 4 mg/min. There is some evidence that after 5 days of infusion, there is an increased risk of accumulation of the toxic metabolite monoethylglycinexylidide.<xref ref-type="bibr" rid="R136"><sup>136</sup></xref> Intravenous lidocaine infusion may offer short-term benefit for patients with TACs and migraine but may be associated with mild AEs.</p><p>Prior to infusion, patients should undergo 12-lead ECG, liver function tests, and liver enzyme tests. Intravenous lidocaine is contraindicated for patients with liver or renal failure. On-site anesthesiologist, local anesthetic systemic toxicity protocol, intralipid, and cardiovascular monitoring should be exclusively and immediately available for patients undergoing continuous lidocaine infusion; providers may also consider monitoring plasma concentrations if available and if results would return in time to affect management.</p></sec><sec id="s3-8-4"><title>Statement</title><list list-content="ul" list-type="bullet"><list-item><p>Intravenous lidocaine infusion may offer benefit for inpatients with TACs and intractable migraine and may be associated with mild AEs. Level of certainty: low</p></list-item></list></sec><sec id="s3-8-5"><title>Recommendation</title><list list-content="ul" list-type="bullet"><list-item><p>Duration of intravenous lidocaine should not routinely exceed 5 days to reduce risks associated with accumulation of a toxic metabolite. If prolonged infusion is warranted, then daily measurement of serum lidocaine levels may be considered. Grade C.</p></list-item></list></sec></sec><sec id="s3-9"><title>What is the evidence for the use of intravenous ketamine for inpatient headache management?</title><sec id="s3-9-1"><title>Mechanism of action</title><p>Ketamine is a dissociative anesthetic agent that possesses potent analgesic effects at subanesthetic doses. It is a non-competitive NMDA antagonist but interacts with multiple other receptors, including kappa-opioid and mu-opioid receptors, nicotinic and muscarinic cholinergic receptors, D2-dopamine receptors, and voltage-gated calcium channels, among others.<xref ref-type="bibr" rid="R137"><sup>137</sup></xref> It has also been shown to have anti-inflammatory properties.<xref ref-type="bibr" rid="R138"><sup>138</sup></xref></p></sec><sec id="s3-9-2"><title>Study findings</title><p>A systematic literature search found five retrospective observational studies (n=183) investigating the effect of ketamine for inpatients specifically. No ED studies were included. It has primarily been studied for headache in patients refractory to standard treatments.<xref ref-type="bibr" rid="R127">127128 139</xref><xref ref-type="bibr" rid="R141">141</xref> While only a few studies have been published, there is some evidence for a dose–response relationship in that longer infusions at higher infusion rates have been suggested to produce greater relief than shorter infusions at lower doses.<xref ref-type="bibr" rid="R128"><sup>128 140</sup></xref></p><p>In a study by Ray <italic toggle="yes">et al</italic>, 34.4% of patients reported at least 50% relief after a multiday infusion, while in a study by Schwenk <italic toggle="yes">et al</italic> the mean pain of 7.5/10 decreased to 3.4/10 at the end of infusion.<xref ref-type="bibr" rid="R128"><sup>128 140</sup></xref></p><p>Outcome measures across studies have not been consistent, with one study measuring the proportion of patients with a 50% reduction in pain<xref ref-type="bibr" rid="R128"><sup>128</sup></xref> and the others reporting changes in the Numerical Rating Scale.<xref ref-type="bibr" rid="R127">127</xref><xref ref-type="bibr" rid="R142">129142</xref> This may be related to variation in study design, including dosing and patient selection. It is not clear which patients would benefit most from ketamine infusion in terms of overall severity and status of disease (ie, stable vs acute exacerbation). Because primarily refractory patients have been studied, baseline pain levels of those treated with multi-day infusions have generally been in the severe range; in a study of six patients, they all had Migraine Disability Assessment scores of grade 4 at the time of treatment, indicating the greatest degree of disability.<xref ref-type="bibr" rid="R140"><sup>140</sup></xref> Similar to the issue of timing, the frequency of repeated treatments has not been directly addressed.</p></sec><sec id="s3-9-3"><title>Adverse events</title><p>Ketamine has been associated with transient worsening of liver function in some patients, which may limit the frequency of repeated treatments.<xref ref-type="bibr" rid="R143"><sup>143 144</sup></xref> We recommend performing a baseline hepatic function panel prior to treatment and repeating this at the end of treatment at a minimum. More frequent monitoring may be indicated in patients with a history of elevated liver enzymes or in those who are also prescribed intranasal ketamine on an outpatient basis. While the clinical significance of liver enzyme elevation from ketamine is not entirely known, we suggest decreasing the dose in patients with mild to moderate increases (≤10 times the upper limit of normal) and stopping the infusion for those with marked elevation (&gt;10 times the upper limit of normal). There have been documented cases of symptomatic liver injury from prolonged ketamine infusions, all of which improved on ketamine cessation.<xref ref-type="bibr" rid="R144"><sup>144</sup></xref> The side effect profile of ketamine includes sympathomimetic effects (hypertension and tachycardia), psychomimetic effects (anxiety, hallucinations, nightmares, vivid dreams, and out-of-body experiences), hepatic toxicity, nausea and vomiting, blurry vision, and urinary retention, among others.<xref ref-type="bibr" rid="R140">140145</xref><xref ref-type="bibr" rid="R147">147</xref> Several authors and reviews have reported that ketamine’s psychomimetic adverse effects can be mitigated by benzodiazepines and clonidine.<xref ref-type="bibr" rid="R148"><sup>148 149</sup></xref> Some experts recommend the use of a clonidine patch for all normotensive patients and PRN benzodiazepines for more severe adverse effects.<xref ref-type="bibr" rid="R140"><sup>140</sup></xref></p><p>In one study by Schwenk <italic toggle="yes">et al</italic>, about half of the patients treated with a 5-day ketamine infusion experienced sedation, 37.7% had nausea or vomiting, 37.7% had blurry vision, and 27.9% reported hallucinations.<xref ref-type="bibr" rid="R140"><sup>140</sup></xref> Patients in that study received a mean ketamine infusion rate of 0.76 mg/kg/hour. In healthy volunteers, ketamine increases heart rate and blood pressure but usually does not lead to hypertensive events.<xref ref-type="bibr" rid="R150"><sup>150</sup></xref> Nevertheless, hypertensive events with ketamine infusions may occur, and this can occasionally limit the tolerated maximal dose.</p><p>In terms of suggested personnel and monitoring, the committee recommends following the recommendations proposed in the 2018 ASRA PM guidelines for ketamine infusions for chronic pain, which stated that the ordering physician should be an anesthesiologist, critical care physician, or pain physician experienced with ketamine and trained in both Advanced Cardiac Life Support and administration of moderate sedation.<xref ref-type="bibr" rid="R137"><sup>137</sup></xref></p><p>While the guidelines did not specify exact monitors to be used for doses under 1 mg/kg/hour, the committee recommends telemetry be used for all patients unless close observation can be assured by an acute pain service or other personnel experienced with ketamine’s adverse effects. In addition to telemetry, blood pressure and pulse oximetry should be checked at a minimum of every 4 hours.</p><p>In summary, based on available evidence, the committee recommends ketamine infusions for patients with refractory headache be offered selectively based on physician and treatment center experience.</p></sec><sec id="s3-9-4"><title>Statements</title><list list-content="ul" list-type="bullet"><list-item><p>Ketamine infusions may provide benefit in acute treatment of intractable headache. Level of certainty: low</p></list-item><list-item><p>Adverse effects can occur even at subanesthetic doses. Level of certainty: high</p></list-item><list-item><p>The incidence and severity of psychotomimetic and sympathomimetic effects from ketamine may be reduced by administration of clonidine or benzodiazepines. Level of certainty: moderate</p></list-item></list></sec><sec id="s3-9-5"><title>Recommendations</title><list list-content="ul" list-type="bullet"><list-item><p>Ketamine infusions may be considered in the acute inpatient treatment of refractory headache. Grade C.</p></list-item><list-item><p>Ketamine infusion rates should not exceed 1 mg/kg/hour outside of intensive care unit settings. Grade B.</p></list-item><list-item><p>Patients should be under continuous respiratory and hemodynamic monitoring while receiving ketamine infusions. Grade B.</p></list-item><list-item><p>Consider administering clonidine and/or a low-dose benzodiazepine to partially mitigate psychotomimetic and sympathomimetic adverse effects of ketamine. Grade C.</p></list-item></list></sec></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal findings</title><p>The goal of this document was to provide structured and evidence-based statements and recommendations on intravenous drug administration specifically for the hospitalized headache patient. Although numerous headache management articles are available, they are primarily focused on the outpatient population. The evidence level for most of the medications included in this consensus document is low, and as a result, the strength for most recommendations is Grade C, indicating that the drug could be considered for selected patients in specific circumstances.</p><p>When there were limited data available from the inpatient literature, we extrapolated data from relevant ED literature and noted these instances.</p></sec><sec id="s4-2"><title>Interpretation</title><p>Despite the overall weak evidence base, this review has provided valuable insights into the current evidence for each drug treatment in the inpatient setting and highlighted areas where more research is needed. Ultimately, this practice advisory aims to provide the first evidence-based recommendations for intravenous headache management specifically tailored to the inpatient population.</p></sec><sec id="s4-3"><title>Clinical implications</title><p>Parenteral pharmacological treatment typically includes a combination of DHE, NSAIDs, antiemetics, antiepileptics, magnesium, corticosteroids, lidocaine, and ketamine, all tailored to the specific headache patient.<xref ref-type="bibr" rid="R151"><sup>151</sup></xref> These recommendations aim to provide additional options for providers to consider. While opioids are commonly prescribed for acute headache treatment, they should be avoided due to their limited effectiveness in pain relief, association with increased ED return rates, and long-term risk of tolerance, dependence, and addiction.<xref ref-type="bibr" rid="R152"><sup>152 153</sup></xref></p><p>Our literature review suggests that intravenous inpatient pharmacological management is effective, often producing rapid results. However, the goals of admission should include validation of correct diagnosis and restoration of function and quality of life, in addition to the reduction of pain and other disabling headache-related symptoms. Key objectives include aborting the current headache attack, preventing headache recurrence, addressing associated symptoms, optimizing preventive and acute home treatment, and incorporating biobehavioral and nonpharmacological treatments.<xref ref-type="bibr" rid="R154"><sup>154</sup></xref> Postdischarge follow-up is essential to ensure the effectiveness of new or adjusted medications and to provide patient support and education.</p></sec><sec id="s4-4"><title>Limitations</title><p>While many of the medications have an established track record in treating headache in the outpatient setting, this review specifically examined their use in the inpatient population.</p><p>Unfortunately, the quality of the included studies was often low to moderate. Most studies were observational and limited by sample sizes. Further, heterogeneity in study population, intervention, and duration of follow-up, as well as lack of standardized outcome measures and publication bias, made it challenging to provide recommendations with a high level of certainty. For some widely recognized and well-established drugs, the evidence grading was lower than anticipated as compared with their effectiveness witnessed in the outpatient headache setting.</p><p>Additionally, ED data were included in several questions to allow for conclusions to be drawn, and this indirectness could have reduced the overall quality of the recommendation.</p></sec><sec id="s4-5"><title>Future directions</title><p>These findings, therefore, underscore the need for targeted high-quality research in this specific patient population. Prospective trials are needed to assess and compare these intravenous infusions, alone or in combination, their dose–response relationship, and effect on pain-associated domains, specifically in the inpatient setting. More studies are also needed to evaluate the effect of single and repeated hospitalizations for infusion therapy with assessment of subacute to long-term outcomes.</p></sec></sec><sec id="s5" sec-type="conclusions"><title>Conclusions</title><p>Hospitalized patients with refractory headaches present unique challenges to the healthcare system. This evidence-based practice advisory provides a foundational step toward standardizing inpatient headache care and highlights existing gaps in our knowledge and the literature that should be addressed through rigorous prospective randomized studies.</p></sec><sec id="s6" sec-type="supplementary-material"><title>Supplementary material</title><supplementary-material content-type="local-data" id="SP1" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1136/rapm-2025-106718</object-id><label>online supplemental file 1</label><media id="d67e1726" orientation="portrait" position="anchor" xlink:href="rapm-51-2-s001.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material><supplementary-material content-type="local-data" id="SP2" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1136/rapm-2025-106718</object-id><label>online supplemental file 2</label><media id="d67e1731" orientation="portrait" position="anchor" xlink:href="rapm-51-2-s002.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Correction notice:</bold> This article has been corrected since it published Online First. The statement and recommendation on Ketorolac and table 3 have both been updated.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Burch</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Rizzoli</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Loder</surname><given-names>E</given-names></name>
</person-group><article-title>The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys</article-title><source>Headache</source><year>2021</year><volume>61</volume><fpage>60</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/head.14024</pub-id><pub-id pub-id-type="pmid">33349955</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kiarashi</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Jion</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Giglio</surname><given-names>B</given-names></name>
<etal>et al</etal>
</person-group><article-title>Elective Hospitalizations for Intractable Headache: Outcomes and Response Predictors</article-title><source>Neurol Clin Pract</source><year>2021</year><volume>11</volume><fpage>188</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1212/CPJ.0000000000000965</pub-id><pub-id pub-id-type="pmid">34484886</pub-id><pub-id pub-id-type="pmcid">PMC8382342</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Insinga</surname><given-names>RP</given-names></name>
<name name-style="western"><surname>Ng-Mak</surname><given-names>DS</given-names></name>
<name name-style="western"><surname>Hanson</surname><given-names>ME</given-names></name>
</person-group><article-title>Costs associated with outpatient, emergency room and inpatient care for migraine in the USA</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>1570</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1177/0333102411425960</pub-id><pub-id pub-id-type="pmid">22013140</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Robblee</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Grimsrud</surname><given-names>KW</given-names></name>
</person-group><article-title>Emergency Department and Inpatient Management of Headache in Adults</article-title><source>Curr Neurol Neurosci Rep</source><year>2020</year><volume>20</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1007/s11910-020-01030-w</pub-id><pub-id pub-id-type="pmid">32189074</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lai</surname><given-names>TH</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>SJ</given-names></name>
</person-group><article-title>Update of Inpatient Treatment for Refractory Chronic Daily Headache</article-title><source>Curr Pain Headache Rep</source><year>2016</year><volume>20</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1007/s11916-015-0531-y</pub-id><pub-id pub-id-type="pmid">26707496</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dominguez</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Minen</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Robbins</surname><given-names>MS</given-names></name>
</person-group><article-title>Educational initiatives in headache medicine: A 20-year scoping review</article-title><source>Headache</source><year>2023</year><volume>63</volume><fpage>861</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1111/head.14541</pub-id><pub-id pub-id-type="pmid">37382041</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kristoffersen</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Faiz</surname><given-names>KW</given-names></name>
<name name-style="western"><surname>Winsvold</surname><given-names>BS</given-names></name>
</person-group><article-title>Neurology residents’ knowledge of the management of headache</article-title><source>Cephalalgia</source><year>2019</year><volume>39</volume><fpage>1396</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1177/0333102419847973</pub-id><pub-id pub-id-type="pmid">31067081</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gallagher</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Alam</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Headache in Medical Education: Medical Schools, Neurology and Family Practice Residencies</article-title><source>Headache</source><year>2005</year><volume>45</volume><fpage>866</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.05155.x</pub-id><pub-id pub-id-type="pmid">15985103</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>USPSTF</collab>
</person-group><article-title>Grade definitions after 2012</article-title><year>2025</year><comment>Available</comment><ext-link ext-link-type="uri" xlink:href="www.uspreventiveservicestaskforce.org/uspstf/about-%20uspstf/methods-and-processes/grade-definitions#july2012" xmlns:xlink="http://www.w3.org/1999/xlink">www.uspreventiveservicestaskforce.org/uspstf/about- uspstf/methods-and-processes/grade-definitions#july2012</ext-link></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Diamond</surname><given-names>IR</given-names></name>
<name name-style="western"><surname>Grant</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Feldman</surname><given-names>BM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies</article-title><source>J Clin Epidemiol</source><year>2014</year><volume>67</volume><fpage>401</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.12.002</pub-id><pub-id pub-id-type="pmid">24581294</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Taylor</surname><given-names>E</given-names></name>
</person-group><article-title>We Agree, Don’t We? The Delphi Method for Health Environments Research</article-title><source>HERD</source><year>2020</year><volume>13</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1177/1937586719887709</pub-id><pub-id pub-id-type="pmid">31887097</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Uppal</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Russell</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Kalagara</surname><given-names>H</given-names></name>
<etal>et al</etal>
</person-group><article-title>Evidence-based clinical practice guidelines on postdural puncture headache: infographics</article-title><source>Reg Anesth Pain Med</source><year>2024</year><volume>49</volume><fpage>502</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1136/rapm-2024-105280</pub-id><pub-id pub-id-type="pmid">38373816</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shah</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Schwenk</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Sondekoppam</surname><given-names>RV</given-names></name>
<etal>et al</etal>
</person-group><article-title>ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids</article-title><source>Reg Anesth Pain Med</source><year>2023</year><volume>48</volume><fpage>97</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1136/rapm-2022-104013</pub-id><pub-id pub-id-type="pmid">36596580</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>
<name name-style="western"><surname>Shrewsbury</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Hoekman</surname><given-names>J</given-names></name>
</person-group><article-title>Dihydroergotamine (DHE) – Then and Now: A Narrative Review</article-title><source>
<italic toggle="yes">Headache</italic>
</source><year>2020</year><volume>60</volume><fpage>40</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/head.13700</pub-id><pub-id pub-id-type="pmid">31737909</pub-id><pub-id pub-id-type="pmcid">PMC7003832</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>
</person-group><article-title>The pharmacology of headache</article-title><source>Prog Neurobiol</source><year>2000</year><volume>62</volume><fpage>509</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/s0301-0082(00)00010-1</pub-id><pub-id pub-id-type="pmid">10869781</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Buzzi</surname><given-names>MG</given-names></name>
<name name-style="western"><surname>Moskowitz</surname><given-names>MA</given-names></name>
</person-group><article-title>Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine</article-title><source>Cephalalgia</source><year>1991</year><volume>11</volume><fpage>165</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1991.1104165.x</pub-id><pub-id pub-id-type="pmid">1660351</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hoskin</surname><given-names>KL</given-names></name>
<name name-style="western"><surname>Kaube</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>
</person-group><article-title>Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine</article-title><source>Brain (Bacau)</source><year>1996</year><volume>119</volume><fpage>249</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1093/brain/119.1.249</pub-id><pub-id pub-id-type="pmid">8624686</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Markowitz</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Saito</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Moskowitz</surname><given-names>MA</given-names></name>
</person-group><article-title>Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache</article-title><source>Cephalalgia</source><year>1988</year><volume>8</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1988.0802083.x</pub-id><pub-id pub-id-type="pmid">3401921</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Schürks</surname><given-names>M</given-names></name>
</person-group><article-title>Dihydroergotamine: role in the treatment of migraine</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2009</year><volume>5</volume><fpage>1141</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1517/17425250903164211</pub-id><pub-id pub-id-type="pmid">19624283</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>
<name name-style="western"><surname>Schulman</surname><given-names>EA</given-names></name>
<name name-style="western"><surname>Hopkins</surname><given-names>MM</given-names></name>
</person-group><article-title>Repetitive intravenous DHE in the treatment of refractory headache</article-title><source>Headache</source><year>1990</year><volume>30</volume><fpage>334</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1990.hed3006334.x</pub-id><pub-id pub-id-type="pmid">2370132</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pringsheim</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Howse</surname><given-names>D</given-names></name>
</person-group><article-title>In-Patient Treatment of Chronic Daily Headache Using Dihydroergotamine: a Long-term Follow-up Study</article-title><source>Can j neurol sci</source><year>1998</year><volume>25</volume><fpage>146</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1017/S031716710003376X</pub-id><pub-id pub-id-type="pmid">9604137</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ford</surname><given-names>RG</given-names></name>
<name name-style="western"><surname>Ford</surname><given-names>KT</given-names></name>
</person-group><article-title>Continuous intravenous dihydroergotamine in the treatment of intractable headache</article-title><source>Headache</source><year>1997</year><volume>37</volume><fpage>129</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.1997.3703129.x</pub-id><pub-id pub-id-type="pmid">9100396</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Swidan</surname><given-names>SZ</given-names></name>
<name name-style="western"><surname>Lake</surname><given-names>AE</given-names></name>
<name name-style="western"><surname>Saper</surname><given-names>JR</given-names></name>
</person-group><article-title>Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache</article-title><source>Curr Pain Headache Rep</source><year>2005</year><volume>9</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/s11916-005-0077-5</pub-id><pub-id pub-id-type="pmid">15625028</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jauslin</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Lance</surname><given-names>JW</given-names></name>
</person-group><article-title>The hospital management of severe migrainous headache</article-title><source>Headache</source><year>1991</year><volume>31</volume><fpage>658</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1991.hed3110658.x</pub-id><pub-id pub-id-type="pmid">1663091</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nagy</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Gandhi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Bhola</surname><given-names>R</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous dihydroergotamine for inpatient management of refractory primary headaches</article-title><source>Neurology (ECronicon)</source><year>2011</year><volume>77</volume><fpage>1827</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182377dbb</pub-id><pub-id pub-id-type="pmid">22049203</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>
<name name-style="western"><surname>Silberstein</surname><given-names>JR</given-names></name>
</person-group><article-title>Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE</article-title><source>Headache</source><year>1992</year><volume>32</volume><fpage>439</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1992.hed3209439.x</pub-id><pub-id pub-id-type="pmid">1446987</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Raskin</surname><given-names>NH</given-names></name>
</person-group><article-title>Repetitive intravenous dihydroergotamine as therapy for intractable migraine</article-title><source>Neurology (ECronicon)</source><year>1986</year><volume>36</volume><fpage>995</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1212/wnl.36.7.995</pub-id><pub-id pub-id-type="pmid">3520384</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mather</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>
<name name-style="western"><surname>Schulman</surname><given-names>EA</given-names></name>
<etal>et al</etal>
</person-group><article-title>The treatment of cluster headache with repetitive intravenous dihydroergotamine</article-title><source>Headache</source><year>1991</year><volume>31</volume><fpage>525</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1991.hed3108525.x</pub-id><pub-id pub-id-type="pmid">1960057</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lambru</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Shanahan</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Matharu</surname><given-names>M</given-names></name>
</person-group><article-title>Exacerbation of SUNCT and SUNA syndromes during intravenous dihydroergotamine treatment: A case series</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>2015</year><volume>35</volume><fpage>1115</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1177/0333102415570495</pub-id><pub-id pub-id-type="pmid">25667300</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Coppola</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Yealy</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Leibold</surname><given-names>RA</given-names></name>
</person-group><article-title>Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache</article-title><source>Ann Emerg Med</source><year>1995</year><volume>26</volume><fpage>541</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/s0196-0644(95)70001-3</pub-id><pub-id pub-id-type="pmid">7486359</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jones</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Pack</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Chun</surname><given-names>E</given-names></name>
</person-group><article-title>Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache</article-title><source>Am J Emerg Med</source><year>1996</year><volume>14</volume><fpage>262</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0735-6757(96)90171-0</pub-id><pub-id pub-id-type="pmid">8639197</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bekan</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Tfelt-Hansen</surname><given-names>P</given-names></name>
</person-group><article-title>Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong 'General Consensus' of One Trial? A Critical Review of the Trial and Subsequent Quotations</article-title><source>Headache</source><year>2016</year><volume>56</volume><fpage>1482</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/head.12904</pub-id><pub-id pub-id-type="pmid">27595607</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Queiroz</surname><given-names>LP</given-names></name>
<name name-style="western"><surname>Weeks</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Rapoport</surname><given-names>AM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Early and transient side effects of repetitive intravenous dihydroergotamine</article-title><source>Headache</source><year>1996</year><volume>36</volume><fpage>291</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.1996.3605291.x</pub-id><pub-id pub-id-type="pmid">8682669</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Eller</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gelfand</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Riggins</surname><given-names>NY</given-names></name>
<etal>et al</etal>
</person-group><article-title>Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome</article-title><source>Neurology (ECronicon)</source><year>2016</year><volume>86</volume><fpage>856</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002406</pub-id><pub-id pub-id-type="pmcid">PMC4793780</pub-id><pub-id pub-id-type="pmid">26843569</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tso</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Patniyot</surname><given-names>IR</given-names></name>
<name name-style="western"><surname>Gelfand</surname><given-names>AA</given-names></name>
<etal>et al</etal>
</person-group><article-title>Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment</article-title><source>Neurology (ECronicon)</source><year>2017</year><volume>89</volume><fpage>279</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004108</pub-id><pub-id pub-id-type="pmcid">PMC5513820</pub-id><pub-id pub-id-type="pmid">28615428</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cete</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Dora</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Ertan</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>A Randomized Prospective Placebo-Controlled Study of Intravenous Magnesium Sulphate vs. Metoclopramide in the Management of Acute Migraine Attacks in the Emergency Department</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>2005</year><volume>25</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00840.x</pub-id><pub-id pub-id-type="pmid">15689195</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sarchielli</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Coata</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Firenze</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>Serum and Salivary Magnesium Levels in Migraine and Tension-Type Headache. Results in a Group of Adult Patients</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>1992</year><volume>12</volume><fpage>21</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1992.1201021.x</pub-id><pub-id pub-id-type="pmid">1559254</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ramadan</surname><given-names>NM</given-names></name>
<name name-style="western"><surname>Halvorson</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Vande-Linde</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Low brain magnesium in migraine</article-title><source>Headache</source><year>1989</year><volume>29</volume><fpage>416</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1989.hed2907416.x</pub-id><pub-id pub-id-type="pmid">2759849</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Demirkaya</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Vural</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Dora</surname><given-names>B</given-names></name>
<etal>et al</etal>
</person-group><article-title>Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks</article-title><source>Headache</source><year>2001</year><volume>41</volume><fpage>171</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2001.111006171.x</pub-id><pub-id pub-id-type="pmid">11251702</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shahrami</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Assarzadegan</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Hatamabadi</surname><given-names>HR</given-names></name>
<etal>et al</etal>
</person-group><article-title>Comparison of therapeutic effects of magnesium sulfate vs. dexamethasone/metoclopramide on alleviating acute migraine headache</article-title><source>J Emerg Med</source><year>2015</year><volume>48</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2014.06.055</pub-id><pub-id pub-id-type="pmid">25278139</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zidverc-Trajković</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Pavlović</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Jovanović</surname><given-names>Z</given-names></name>
<etal>et al</etal>
</person-group><article-title>Efficacy of intravenous magnesium sulfate in severe migraine attacks</article-title><source>J Headache Pain</source><year>2001</year><volume>2</volume><fpage>79</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/PL00012190</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kandil</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Jaber</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Desai</surname><given-names>D</given-names></name>
<etal>et al</etal>
</person-group><article-title>MAGraine: Magnesium compared to conventional therapy for treatment of migraines</article-title><source>Am J Emerg Med</source><year>2021</year><volume>39</volume><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2020.09.033</pub-id><pub-id pub-id-type="pmid">33041146</pub-id><pub-id pub-id-type="pmcid">PMC7489225</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mauskop</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Altura</surname><given-names>BT</given-names></name>
<name name-style="western"><surname>Cracco</surname><given-names>RQ</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous Magnesium Sulphate Relieves Migraine Attacks in Patients with Low Serum Ionized Magnesium Levels: A Pilot Study</article-title><source>Clin Sci</source><year>1995</year><volume>89</volume><fpage>633</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1042/cs0890633</pub-id><pub-id pub-id-type="pmid">8549082</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mauskop</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Altura</surname><given-names>BT</given-names></name>
<name name-style="western"><surname>Cracco</surname><given-names>RQ</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous magnesium sulfate rapidly alleviates headaches of various types</article-title><source>Headache</source><year>1996</year><volume>36</volume><fpage>154</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.1996.3603154.x</pub-id><pub-id pub-id-type="pmid">8984087</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Corbo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Esses</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Bijur</surname><given-names>PE</given-names></name>
<etal>et al</etal>
</person-group><article-title>Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache</article-title><source>Ann Emerg Med</source><year>2001</year><volume>38</volume><fpage>621</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1067/mem.2001.119424</pub-id><pub-id pub-id-type="pmid">11719739</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ginder</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Oatman</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Pollack</surname><given-names>M</given-names></name>
</person-group><article-title>A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches</article-title><source>J Emerg Med</source><year>2000</year><volume>18</volume><fpage>311</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/s0736-4679(99)00220-6</pub-id><pub-id pub-id-type="pmid">10729668</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bigal</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Bordini</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Tepper</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous Magnesium Sulphate in the Acute Treatment of Migraine Without Aura and Migraine with Aura. A Randomized, Double-Blind, Placebo-Controlled Study</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>2002</year><volume>22</volume><fpage>345</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00364.x</pub-id><pub-id pub-id-type="pmid">12110110</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rozen</surname><given-names>TD</given-names></name>
</person-group><article-title>Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulfate</article-title><source>Headache</source><year>2003</year><volume>43</volume><fpage>901</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12940813</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Motamed</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Mozafari</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Porozan</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Magnesium sulfate and acute migraine: A randomized clinical trial</article-title><source>
<italic toggle="yes">Ann Clin Anal Med</italic>
</source><year>2020</year><volume>11</volume><fpage>369</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.4328/ACAM.20072</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Brown</surname><given-names>BL</given-names></name>
<name name-style="western"><surname>Craycraft</surname><given-names>LK</given-names></name>
<name name-style="western"><surname>Justice</surname><given-names>SB</given-names></name>
</person-group><article-title>Valproic Acid in the Treatment of Migraines</article-title><source>Adv Emerg Nurs J</source><year>2020</year><volume>42</volume><fpage>243</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1097/TME.0000000000000319</pub-id><pub-id pub-id-type="pmid">33105176</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ailani</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Burch</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Robbins</surname><given-names>MS</given-names></name>
<etal>et al</etal>
</person-group><article-title>The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice</article-title><source>Headache</source><year>2021</year><volume>61</volume><fpage>1021</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/head.14153</pub-id><pub-id pub-id-type="pmid">34160823</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Orr</surname><given-names>SL</given-names></name>
<name name-style="western"><surname>Friedman</surname><given-names>BW</given-names></name>
<name name-style="western"><surname>Christie</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies</article-title><source>Headache</source><year>2016</year><volume>56</volume><fpage>911</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/head.12835</pub-id><pub-id pub-id-type="pmid">27300483</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous sodium valproate for acute migraine in the emergency department: A meta-analysis</article-title><source>Acta Neurol Scand</source><year>2020</year><volume>142</volume><fpage>521</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/ane.13325</pub-id><pub-id pub-id-type="pmid">32740903</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dogruyol</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Gur</surname><given-names>STA</given-names></name>
<name name-style="western"><surname>Akbas</surname><given-names>I</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial</article-title><source>Am J Emerg Med</source><year>2022</year><volume>55</volume><fpage>126</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2022.02.046</pub-id><pub-id pub-id-type="pmid">35313227</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rahimdel</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Mellat</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Zeinali</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial</article-title><source>Iran J Med Sci</source><year>2014</year><volume>39</volume><fpage>171</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24753639</pub-id><pub-id pub-id-type="pmcid">PMC3993044</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Stillman</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Zajac</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Rybicki</surname><given-names>LA</given-names></name>
</person-group><article-title>Treatment of primary headache disorders with intravenous valproate: initial outpatient experience</article-title><source>Headache</source><year>2004</year><volume>44</volume><fpage>65</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2004.04010.x</pub-id><pub-id pub-id-type="pmid">14979885</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shahien</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Saleh</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Bowirrat</surname><given-names>A</given-names></name>
</person-group><article-title>Intravenous sodium valproate aborts migraine headaches rapidly</article-title><source>Acta Neurol Scand</source><year>2011</year><volume>123</volume><fpage>257</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.2010.01394.x</pub-id><pub-id pub-id-type="pmid">20569223</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Schwartz</surname><given-names>TH</given-names></name>
<name name-style="western"><surname>Karpitskiy</surname><given-names>VV</given-names></name>
<name name-style="western"><surname>Sohn</surname><given-names>RS</given-names></name>
</person-group><article-title>Intravenous Valproate Sodium in the Treatment of Daily Headache</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>519</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.02127.x</pub-id><pub-id pub-id-type="pmid">12167141</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Riggins</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Ehrlich</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sawhney</surname><given-names>H</given-names></name>
<etal>et al</etal>
</person-group><article-title>Retrospective Chart Review of Intravenous Valproate Sodium as a Preventive Treatment for Patients With Chronic Migraine</article-title><source>Headache</source><year>2020</year><volume>60</volume><fpage>617</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/head.13756</pub-id><pub-id pub-id-type="pmid">31985052</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cook</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Zafar</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Mathias</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion</article-title><source>CNS Drugs</source><year>2016</year><volume>30</volume><fpage>71</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s40263-015-0304-5</pub-id><pub-id pub-id-type="pmid">26715390</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Georgoff</surname><given-names>PE</given-names></name>
<name name-style="western"><surname>Nikolian</surname><given-names>VC</given-names></name>
<name name-style="western"><surname>Bonham</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial</article-title><source>Clin Pharmacokinet</source><year>2018</year><volume>57</volume><fpage>209</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/s40262-017-0553-1</pub-id><pub-id pub-id-type="pmid">28497259</pub-id><pub-id pub-id-type="pmcid">PMC5699961</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jakubowski</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Levy</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Goor-Aryeh</surname><given-names>I</given-names></name>
<etal>et al</etal>
</person-group><article-title>Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors</article-title><source>Headache</source><year>2005</year><volume>45</volume><fpage>850</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.05153.x</pub-id><pub-id pub-id-type="pmid">15985101</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>X-C</given-names></name>
<name name-style="western"><surname>Kainz</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Burstein</surname><given-names>R</given-names></name>
<etal>et al</etal>
</person-group><article-title>Tumor necrosis factor-α induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions</article-title><source>Pain</source><year>2011</year><volume>152</volume><fpage>140</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2010.10.002</pub-id><pub-id pub-id-type="pmid">21036476</pub-id><pub-id pub-id-type="pmcid">PMC3391748</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pardutz</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Schoenen</surname><given-names>J</given-names></name>
</person-group><article-title>NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data</article-title><source>Pharmaceuticals (Basel)</source><year>2010</year><volume>3</volume><fpage>1966</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3390/ph3061966</pub-id><pub-id pub-id-type="pmid">27713337</pub-id><pub-id pub-id-type="pmcid">PMC4033962</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Richer</surname><given-names>LP</given-names></name>
<name name-style="western"><surname>Ali</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>DW</given-names></name>
<etal>et al</etal>
</person-group><article-title>A randomized trial of ketorolac and metoclopramide for migraine in the emergency department</article-title><source>Headache</source><year>2022</year><volume>62</volume><fpage>681</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/head.14307</pub-id><pub-id pub-id-type="pmid">35670115</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Vadivelu</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Gowda</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Urman</surname><given-names>RD</given-names></name>
<etal>et al</etal>
</person-group><article-title>Ketorolac Tromethamine – Routes and Clinical Implications</article-title><source>Pain Pract</source><year>2015</year><volume>15</volume><fpage>175</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/papr.12198</pub-id><pub-id pub-id-type="pmid">24738596</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Seim</surname><given-names>MB</given-names></name>
<name name-style="western"><surname>March</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Dunn</surname><given-names>KA</given-names></name>
</person-group><article-title>Intravenous Ketorolac vs Intravenous Prochlorperazine for the Treatment of Migraine Headaches</article-title><source>Acad Emerg Med</source><year>1998</year><volume>5</volume><fpage>573</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1553-2712.1998.tb02463.x</pub-id><pub-id pub-id-type="pmid">9660282</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nurathirah</surname><given-names>MN</given-names></name>
<name name-style="western"><surname>Yazid</surname><given-names>MB</given-names></name>
<name name-style="western"><surname>Norhayati</surname><given-names>MN</given-names></name>
<etal>et al</etal>
</person-group><article-title>Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta‐analysis</article-title><source>Acad Emerg Med</source><year>2022</year><volume>29</volume><fpage>1118</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/acem.14457</pub-id><pub-id pub-id-type="pmid">35138658</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Friedman</surname><given-names>BW</given-names></name>
<name name-style="western"><surname>Garber</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Yoon</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine</article-title><source>Neurology (ECronicon)</source><year>2014</year><volume>82</volume><fpage>976</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000223</pub-id><pub-id pub-id-type="pmid">24523483</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Litvak</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>McEvoy</surname><given-names>GK</given-names></name>
</person-group><article-title>Ketorolac, an injectable nonnarcotic analgesic</article-title><source>Clin Pharm</source><year>1990</year><volume>9</volume><fpage>921</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">2292174</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Arfè</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Scotti</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Varas-Lorenzo</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study</article-title><source>BMJ</source><year>2016</year><volume>354</volume><elocation-id>i4857</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.i4857</pub-id><pub-id pub-id-type="pmid">27682515</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Strom</surname><given-names>BL</given-names></name>
<name name-style="western"><surname>Berlin</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Kinman</surname><given-names>JL</given-names></name>
<etal>et al</etal>
</person-group><article-title>Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study</article-title><source>JAMA</source><year>1996</year><volume>275</volume><fpage>376</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8569017</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Motov</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Yasavolian</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Likourezos</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial</article-title><source>Ann Emerg Med</source><year>2017</year><volume>70</volume><fpage>177</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2016.10.014</pub-id><pub-id pub-id-type="pmid">27993418</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Marmura</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>
<name name-style="western"><surname>Schwedt</surname><given-names>TJ</given-names></name>
</person-group><article-title>The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies</article-title><source>Headache J Head Face Pain</source><year>2015</year><volume>55</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/head.12499</pub-id><pub-id pub-id-type="pmid">25600718</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Woldeamanuel</surname><given-names>YW</given-names></name>
<name name-style="western"><surname>Rapoport</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Cowan</surname><given-names>RP</given-names></name>
</person-group><article-title>The place of corticosteroids in migraine attack management: A 65-year systematic review with pooled analysis and critical appraisal</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>2015</year><volume>35</volume><fpage>996</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1177/0333102414566200</pub-id><pub-id pub-id-type="pmid">25576463</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Oray</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Abu Samra</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Ebrahimiadib</surname><given-names>N</given-names></name>
<etal>et al</etal>
</person-group><article-title>Long-term side effects of glucocorticoids</article-title><source>Expert Opin Drug Saf</source><year>2016</year><volume>15</volume><fpage>457</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1517/14740338.2016.1140743</pub-id><pub-id pub-id-type="pmid">26789102</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Evers</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Afra</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Frese</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force</article-title><source>Eur J Neurol</source><year>2009</year><volume>16</volume><fpage>968</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02748.x</pub-id><pub-id pub-id-type="pmid">19708964</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>May</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Evers</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>
<etal>et al</etal>
</person-group><article-title>European Academy of Neurology guidelines on the treatment of cluster headache</article-title><source>Eur J Neurol</source><year>2023</year><volume>30</volume><fpage>2955</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/ene.15956</pub-id><pub-id pub-id-type="pmid">37515405</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>May</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Leone</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Áfra</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>EFNS guidelines on the treatment of cluster headache and other trigeminal‐autonomic cephalalgias</article-title><source>Euro J of Neurology</source><year>2006</year><volume>13</volume><fpage>1066</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2006.01566.x</pub-id><pub-id pub-id-type="pmid">16987158</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Vernieri</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Pasqualetti</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Paolucci</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Drug withdrawal along with bridge therapy with methylprednisolone and/or diazepam for treatment of medication overuse headache: a preliminary report from the WASH-OUT study</article-title><source>
<italic toggle="yes">Neurol Sci</italic>
</source><year>2020</year><volume>41</volume><fpage>499</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1007/s10072-020-04675-0</pub-id><pub-id pub-id-type="pmid">32856233</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Trucco</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Meineri</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Ruiz</surname><given-names>L</given-names></name>
<etal>et al</etal>
</person-group><article-title>Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache</article-title><source>J Headache Pain</source><year>2005</year><volume>6</volume><fpage>334</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s10194-005-0225-7</pub-id><pub-id pub-id-type="pmid">16362704</pub-id><pub-id pub-id-type="pmcid">PMC3452038</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Valguarnera</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Tanganelli</surname><given-names>P</given-names></name>
</person-group><article-title>The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline</article-title><source>
<italic toggle="yes">Neurol Sci</italic>
</source><year>2010</year><volume>31</volume><fpage>175</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s10072-010-0319-0</pub-id><pub-id pub-id-type="pmid">20464616</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Montes</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Alberca</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Lozano</surname><given-names>P</given-names></name>
<etal>et al</etal>
</person-group><article-title>Statuslike SUNCT in two young women</article-title><source>Headache</source><year>2001</year><volume>41</volume><fpage>826</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2001.01151.x</pub-id><pub-id pub-id-type="pmid">11576210</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Maihöfner</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Speck</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Sperling</surname><given-names>W</given-names></name>
<etal>et al</etal>
</person-group><article-title>Complete remission of SUNCT syndrome by intravenous glucocorticoid treatment</article-title><source>
<italic toggle="yes">Neurol Sci</italic>
</source><year>2013</year><volume>34</volume><fpage>1811</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1007/s10072-012-1282-8</pub-id><pub-id pub-id-type="pmid">23274832</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gurumukhani</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Patel</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Patel</surname><given-names>MV</given-names></name>
<etal>et al</etal>
</person-group><article-title>Short-Lasting Unilateral Neuralgiform Headache Attacks with Conjunctival Injection and Tearing (SUNCT) Status Like Condition: A Rare Case Report and Review of the Literature</article-title><source>TONEUJ</source><year>2020</year><volume>14</volume><fpage>74</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2174/1874205X02014010074</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kawada</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kashihara</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Imamura</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>High-dose intravenous methylprednisolone for the prophylactic treatment of cluster headache</article-title><source>Springerplus</source><year>2013</year><volume>2</volume><elocation-id>156</elocation-id><pub-id pub-id-type="doi">10.1186/2193-1801-2-156</pub-id><pub-id pub-id-type="pmid">23667809</pub-id><pub-id pub-id-type="pmcid">PMC3647094</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Taktakoglu Ozdogru</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Aslan</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Balal</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>High-Dose Intravenous Methylprednisolone Use for Transitional Prophylaxis in Drug - Resistant Cluster Headache</article-title><source>J Neurol Sci Turk</source><year>2014</year><volume>31</volume><fpage>355</fpage><lpage>60</lpage></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Prakash</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Brahmbhatt</surname><given-names>KJ</given-names></name>
<name name-style="western"><surname>Chawda</surname><given-names>NT</given-names></name>
<etal>et al</etal>
</person-group><article-title>Hemicrania continua responsive to intravenous methyl prednisolone</article-title><source>Headache</source><year>2009</year><volume>49</volume><fpage>604</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2008.01269.x</pub-id><pub-id pub-id-type="pmid">19348037</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Abou-Khalil</surname><given-names>BW</given-names></name>
</person-group><article-title>Update on Antiseizure Medications 2022</article-title><source>Continuum (Mount Lawley)</source><year>2022</year><volume>28</volume><fpage>500</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1212/CON.0000000000001104</pub-id><pub-id pub-id-type="pmid">35393968</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Trinka</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Leitinger</surname><given-names>M</given-names></name>
</person-group><article-title>Management of Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus</article-title><source>Continuum (Mount Lawley)</source><year>2022</year><volume>28</volume><fpage>559</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1212/CON.0000000000001103</pub-id><pub-id pub-id-type="pmid">35393970</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Contreras-García</surname><given-names>IJ</given-names></name>
<name name-style="western"><surname>Cárdenas-Rodríguez</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Romo-Mancillas</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Levetiracetam Mechanisms of Action: From Molecules to Systems</article-title><source>Pharmaceuticals (Basel)</source><year>2022</year><volume>15</volume><fpage>475</fpage><pub-id pub-id-type="doi">10.3390/ph15040475</pub-id><pub-id pub-id-type="pmid">35455472</pub-id><pub-id pub-id-type="pmcid">PMC9030752</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Carreno</surname><given-names>M</given-names></name>
</person-group><article-title>Levetiracetam</article-title><source>Drugs Today</source><year>2007</year><volume>43</volume><fpage>769</fpage><pub-id pub-id-type="doi">10.1358/dot.2007.43.11.1136902</pub-id><pub-id pub-id-type="pmid">18174964</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hung</surname><given-names>OL</given-names></name>
<name name-style="western"><surname>Shih</surname><given-names>RD</given-names></name>
</person-group><article-title>Antiepileptic drugs: the old and the new</article-title><source>Emerg Med Clin North Am</source><year>2011</year><volume>29</volume><fpage>141</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.emc.2010.09.004</pub-id><pub-id pub-id-type="pmid">21109110</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Farooq</surname><given-names>MU</given-names></name>
<name name-style="western"><surname>Majid</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Pysh</surname><given-names>JJ</given-names></name>
<etal>et al</etal>
</person-group><article-title>Role of intravenous levetiracetam in status migrainosus</article-title><source>J Headache Pain</source><year>2007</year><volume>8</volume><fpage>143</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/s10194-007-0378-7</pub-id><pub-id pub-id-type="pmid">17497272</pub-id><pub-id pub-id-type="pmcid">PMC3476136</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Krusz</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Daniel</surname><given-names>D</given-names></name>
</person-group><article-title>Levetiracetam, given intravenously, for acute intractable migraines (Abstract)</article-title><source>Eur J Neurol</source><year>2002</year><volume>9</volume><fpage>107</fpage><lpage>64</lpage></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Brighina</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Palermo</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Aloisio</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study</article-title><source>Clin Neuropharmacol</source><year>2006</year><volume>29</volume><fpage>338</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/01.WNF.0000236766.08409.03</pub-id><pub-id pub-id-type="pmid">17095897</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Watkins</surname><given-names>AK</given-names></name>
<name name-style="western"><surname>Gee</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>JN</given-names></name>
</person-group><article-title>Efficacy and safety of levetiracetam for migraine prophylaxis: A systematic review</article-title><source>J Clin Pharm Ther</source><year>2018</year><volume>43</volume><fpage>467</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/jcpt.12715</pub-id><pub-id pub-id-type="pmid">29781197</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yen</surname><given-names>PH</given-names></name>
<name name-style="western"><surname>Kuan</surname><given-names>YC</given-names></name>
<name name-style="western"><surname>Tam</surname><given-names>KW</given-names></name>
<etal>et al</etal>
</person-group><article-title>Efficacy of levetiracetam for migraine prophylaxis: A systematic review and meta-analysis</article-title><source>J Formos Med Assoc</source><year>2021</year><volume>120</volume><fpage>755</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2020.08.020</pub-id><pub-id pub-id-type="pmid">32861551</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Medrea</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Cooper</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Langman</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis</article-title><source>Can J Neurol Sci</source><year>2024</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1017/cjn.2024.285</pub-id><pub-id pub-id-type="pmid">39506371</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ramael</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Daoust</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Otoul</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study</article-title><source>Epilepsia</source><year>2006</year><volume>47</volume><fpage>1128</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2006.00586.x</pub-id><pub-id pub-id-type="pmid">16886975</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Charbit</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Akerman</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>
</person-group><article-title>Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex</article-title><source>J Pharmacol Exp Ther</source><year>2009</year><volume>331</volume><fpage>752</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1124/jpet.109.151951</pub-id><pub-id pub-id-type="pmid">19657051</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Baranoglu Kilinc</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Torun</surname><given-names>IE</given-names></name>
<name name-style="western"><surname>Kilinc</surname><given-names>E</given-names></name>
</person-group><article-title>D2 dopamine receptor-mediated mechanisms of dopaminergic system modulation in in vivo and in vitro experimental models of migraine</article-title><source>Eur J Neurosci</source><year>2024</year><volume>59</volume><fpage>1177</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/ejn.16106</pub-id><pub-id pub-id-type="pmid">37539658</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Watanabe</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kopruszinski</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>Moutal</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine</article-title><source>Brain (Bacau)</source><year>2022</year><volume>145</volume><fpage>2894</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1093/brain/awac104</pub-id><pub-id pub-id-type="pmcid">PMC9890468</pub-id><pub-id pub-id-type="pmid">35325034</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>DaSilva</surname><given-names>AF</given-names></name>
<name name-style="western"><surname>Nascimento</surname><given-names>TD</given-names></name>
<name name-style="western"><surname>Jassar</surname><given-names>H</given-names></name>
<etal>et al</etal>
</person-group><article-title>Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo</article-title><source>Neurology (ECronicon)</source><year>2017</year><volume>88</volume><fpage>1634</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000003861</pub-id><pub-id pub-id-type="pmcid">PMC5405765</pub-id><pub-id pub-id-type="pmid">28356463</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>
</person-group><article-title>Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review) [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology</article-title><source>Neurology (ECronicon)</source><year>2000</year><volume>55</volume><fpage>754</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1212/wnl.55.6.754</pub-id><pub-id pub-id-type="pmid">10993991</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Abdelmonem</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Abdelhay</surname><given-names>HM</given-names></name>
<name name-style="western"><surname>Abdelwadoud</surname><given-names>GT</given-names></name>
<etal>et al</etal>
</person-group><article-title>The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials</article-title><source>BMC Neurol</source><year>2023</year><volume>23</volume><fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s12883-023-03259-7</pub-id><pub-id pub-id-type="pmid">37291500</pub-id><pub-id pub-id-type="pmcid">PMC10249175</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Golikhatir</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Cheraghmakani</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Bozorgi</surname><given-names>F</given-names></name>
<etal>et al</etal>
</person-group><article-title>The Efficacy and Safety of Prochlorperazine in Patients With Acute Migraine: A Systematic Review and Meta-Analysis</article-title><source>Headache</source><year>2019</year><volume>59</volume><fpage>682</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1111/head.13527</pub-id><pub-id pub-id-type="pmid">30990883</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hodgson</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Harding</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Bourke</surname><given-names>EM</given-names></name>
<etal>et al</etal>
</person-group><article-title>A prospective, randomized, double‐blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department</article-title><source>Headache</source><year>2021</year><volume>61</volume><fpage>603</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/head.14091</pub-id><pub-id pub-id-type="pmid">33797074</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cameron</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Lane</surname><given-names>PL</given-names></name>
<name name-style="western"><surname>Speechley</surname><given-names>M</given-names></name>
</person-group><article-title>Intravenous Chlorpromazine vs Intravenous Metoclopramide in Acute Migraine Headache</article-title><source>Acad Emerg Med</source><year>1995</year><volume>2</volume><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1111/j.1553-2712.1995.tb03596.x</pub-id><pub-id pub-id-type="pmid">8521205</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bigal</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Bordini</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Speciali</surname><given-names>JG</given-names></name>
</person-group><article-title>Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial</article-title><source>J Emerg Med</source><year>2002</year><volume>23</volume><fpage>141</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/s0736-4679(02)00502-4</pub-id><pub-id pub-id-type="pmid">12359281</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bigal</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Bordini</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Speciali</surname><given-names>JG</given-names></name>
</person-group><article-title>Intravenous chlorpromazine in the acute treatment of episodic tension-type headache: a randomized, placebo controlled, double-blind study</article-title><source>Arq Neuro-Psiquiatr</source><year>2002</year><volume>60</volume><fpage>537</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1590/S0004-282X2002000400004</pub-id><pub-id pub-id-type="pmid">12244386</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Miner</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Fish</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>SW</given-names></name>
<etal>et al</etal>
</person-group><article-title>Droperidol vs. Prochlorperazine for Benign Headaches in the Emergency Department</article-title><source>Acad Emerg Med</source><year>2001</year><volume>8</volume><fpage>873</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1553-2712.2001.tb01147.x</pub-id><pub-id pub-id-type="pmid">11535479</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Weaver</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Jones</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Chisholm</surname><given-names>CD</given-names></name>
<etal>et al</etal>
</person-group><article-title>Droperidol vs. prochlorperazine for the treatment of acute headache</article-title><source>J Emerg Med</source><year>2004</year><volume>26</volume><fpage>145</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2003.05.005</pub-id><pub-id pub-id-type="pmid">14980334</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Callan</surname><given-names>JE</given-names></name>
<name name-style="western"><surname>Kostic</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Bachrach</surname><given-names>EA</given-names></name>
<etal>et al</etal>
</person-group><article-title>Prochlorperazine vs. Promethazine for Headache Treatment in the Emergency Department: A Randomized Controlled Trial</article-title><source>J Emerg Med</source><year>2008</year><volume>35</volume><fpage>247</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2007.09.047</pub-id><pub-id pub-id-type="pmid">18534808</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>McCoy</surname><given-names>JJ</given-names></name>
<name name-style="western"><surname>Aldy</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Arnall</surname><given-names>E</given-names></name>
<etal>et al</etal>
</person-group><article-title>Treatment of Headache in the Emergency Department: Haloperidol in the Acute Setting (THE-HA Study): A Randomized Clinical Trial</article-title><source>J Emerg Med</source><year>2020</year><volume>59</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2020.04.018</pub-id><pub-id pub-id-type="pmid">32402480</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gaffigan</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Bruner</surname><given-names>DI</given-names></name>
<name name-style="western"><surname>Wason</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>A Randomized Controlled Trial of Intravenous Haloperidol vs. Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department</article-title><source>J Emerg Med</source><year>2015</year><volume>49</volume><fpage>326</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2015.03.023</pub-id><pub-id pub-id-type="pmid">26048068</pub-id></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Regan</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Hoffman</surname><given-names>RS</given-names></name>
<name name-style="western"><surname>Nelson</surname><given-names>LS</given-names></name>
</person-group><article-title>Slower infusion of metoclopramide decreases the rate of akathisia</article-title><source>Am J Emerg Med</source><year>2009</year><volume>27</volume><fpage>475</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2008.03.044</pub-id><pub-id pub-id-type="pmid">19555621</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Egerton‐Warburton</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Povey</surname><given-names>K</given-names></name>
</person-group><article-title>Administration of metoclopramide by infusion or bolus does not affect the incidence of drug‐induced akathisia</article-title><source>
<italic toggle="yes">Emerg Medicine Australasia</italic>
</source><year>2013</year><volume>25</volume><fpage>207</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/1742-6723.12062</pub-id><pub-id pub-id-type="pmid">23759039</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Vinson</surname><given-names>DR</given-names></name>
<name name-style="western"><surname>Migala</surname><given-names>AF</given-names></name>
<name name-style="western"><surname>Quesenberry</surname><given-names>CP</given-names></name>
</person-group><article-title>Slow infusion for the prevention of akathisia induced by prochlorperazine: a randomized controlled trial</article-title><source>J Emerg Med</source><year>2001</year><volume>20</volume><fpage>113</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s0736-4679(00)00297-3</pub-id><pub-id pub-id-type="pmid">11207403</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Parlak</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Atilla</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Cicek</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Rate of metoclopramide infusion affects the severity and incidence of akathisia</article-title><source>
<italic toggle="yes">Emerg Med J</italic>
</source><year>2005</year><volume>22</volume><fpage>621</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1136/emj.2004.014712</pub-id><pub-id pub-id-type="pmid">16113179</pub-id><pub-id pub-id-type="pmcid">PMC1726928</pub-id></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Parlak</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Erdur</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Parlak</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous administration of metoclopramide by 2 min bolus vs 15 min infusion: does it affect the improvement of headache while reducing the side effects?</article-title><source>Postgrad Med J</source><year>2007</year><volume>83</volume><fpage>664</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/pgmj.2007.057570</pub-id><pub-id pub-id-type="pmid">17916877</pub-id><pub-id pub-id-type="pmcid">PMC2600133</pub-id></element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>D’Souza</surname><given-names>RS</given-names></name>
<name name-style="western"><surname>Mercogliano</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Ojukwu</surname><given-names>E</given-names></name>
<etal>et al</etal>
</person-group><article-title>Effects of prophylactic anticholinergic medications to decrease extrapyramidal side effects in patients taking acute antiemetic drugs: a systematic review and meta-analysis</article-title><source>
<italic toggle="yes">Emerg Med J</italic>
</source><year>2018</year><volume>35</volume><fpage>325</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1136/emermed-2017-206944</pub-id><pub-id pub-id-type="pmid">29431143</pub-id></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rosen</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Marmura</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Abbas</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous lidocaine in the treatment of refractory headache: a retrospective case series</article-title><source>Headache</source><year>2009</year><volume>49</volume><fpage>286</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2008.01281.x</pub-id><pub-id pub-id-type="pmid">19222600</pub-id></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Berk</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name>
</person-group><article-title>The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders</article-title><source>Headache</source><year>2018</year><volume>58</volume><fpage>783</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/head.13298</pub-id><pub-id pub-id-type="pmid">29536530</pub-id></element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hand</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Stark</surname><given-names>RJ</given-names></name>
</person-group><article-title>Intravenous lignocaine infusions for severe chronic daily headache</article-title><source>Med J Aust</source><year>2000</year><volume>172</volume><fpage>157</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.2000.tb125538.x</pub-id><pub-id pub-id-type="pmid">10772585</pub-id></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Schwenk</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Walter</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Torjman</surname><given-names>MC</given-names></name>
<etal>et al</etal>
</person-group><article-title>Lidocaine infusions for refractory chronic migraine: a retrospective analysis</article-title><source>Reg Anesth Pain Med</source><year>2022</year><volume>47</volume><fpage>408</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1136/rapm-2021-103180</pub-id><pub-id pub-id-type="pmid">35609890</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Schwenk</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Torjman</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Moaddel</surname><given-names>R</given-names></name>
<etal>et al</etal>
</person-group><article-title>Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis</article-title><source>J Clin Pharmacol</source><year>2021</year><volume>61</volume><fpage>1421</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/jcph.1920</pub-id><pub-id pub-id-type="pmid">34125442</pub-id><pub-id pub-id-type="pmcid">PMC8769496</pub-id></element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ray</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Tsan</surname><given-names>K</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study</article-title><source>Front Neurol</source><year>2022</year><volume>13</volume><elocation-id>842082</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2022.842082</pub-id><pub-id pub-id-type="pmid">35356451</pub-id><pub-id pub-id-type="pmcid">PMC8959588</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gil-Gouveia</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>
</person-group><article-title>Neuropsychiatric Side-Effects of Lidocaine: Examples from the Treatment of Headache and a Review</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>2009</year><volume>29</volume><fpage>496</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2008.01800.x</pub-id><pub-id pub-id-type="pmid">19250287</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Arroyo</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Durán</surname><given-names>XR</given-names></name>
<name name-style="western"><surname>Beldarrain</surname><given-names>MG</given-names></name>
<etal>et al</etal>
</person-group><article-title>Response to Intravenous Lidocaine in a Patient with SUNCT Syndrome</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>2010</year><volume>30</volume><fpage>110</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2009.01871.x</pub-id><pub-id pub-id-type="pmid">19438923</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mulroy</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Armstrong-Scott</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Bergin</surname><given-names>P</given-names></name>
</person-group><article-title>Termination of SUNCT with intravenous lignocaine followed by oral mexiletine</article-title><source>
<italic toggle="yes">Cephalalgia Reports</italic>
</source><year>2018</year><volume>1</volume><fpage>251581631876882</fpage><pub-id pub-id-type="doi">10.1177/2515816318768827</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Matharu</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Cohen</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name>
</person-group><article-title>SUNCT Syndrome Responsive to Intravenous Lidocaine</article-title><source>
<italic toggle="yes">Cephalalgia</italic>
</source><year>2004</year><volume>24</volume><fpage>985</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00886.x</pub-id><pub-id pub-id-type="pmid">15482363</pub-id></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Digala</surname><given-names>LP</given-names></name>
<name name-style="western"><surname>Lucchese</surname><given-names>S</given-names></name>
</person-group><article-title>IV Lidocaine Infusion Leading to the Toxic Levels in Serum Causing Asystole – A Case Report</article-title><source>Headache</source><year>2020</year><volume>60</volume><fpage>269</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/head.13699</pub-id><pub-id pub-id-type="pmid">31743428</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chowdhury</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Duggal</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Koul</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Dramatic response of intravenous lidocaine in a patient with status like SUNA: A case report and brief review of literature</article-title><source>Cephalalgia Rep</source><year>2018</year><volume>1</volume><fpage>251581631880481</fpage><pub-id pub-id-type="doi">10.1177/2515816318804816</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lambru</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Stubberud</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Rantell</surname><given-names>K</given-names></name>
<etal>et al</etal>
</person-group><article-title>Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis</article-title><source>
<italic toggle="yes">J Neurol Neurosurg Psychiatry</italic>
</source><year>2021</year><volume>92</volume><fpage>233</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2020-323999</pub-id><pub-id pub-id-type="pmid">33361408</pub-id><pub-id pub-id-type="pmcid">PMC7892380</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sawyer</surname><given-names>DR</given-names></name>
<name name-style="western"><surname>Ludden</surname><given-names>TM</given-names></name>
<name name-style="western"><surname>Crawford</surname><given-names>MH</given-names></name>
</person-group><article-title>Continuous infusion of lidocaine in patients with cardiac arrhythmias. Unpredictability of plasma concentrations</article-title><source>Arch Intern Med</source><year>1981</year><volume>141</volume><fpage>43</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7447583</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cohen</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Bhatia</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Buvanendran</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists</article-title><source>Reg Anesth Pain Med</source><year>2018</year><volume>43</volume><fpage>521</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1097/AAP.0000000000000808</pub-id><pub-id pub-id-type="pmid">29870458</pub-id><pub-id pub-id-type="pmcid">PMC6023575</pub-id></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>M-H</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C-T</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>W-C</given-names></name>
<etal>et al</etal>
</person-group><article-title>Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study</article-title><source>Psychiatry Res</source><year>2018</year><volume>269</volume><fpage>207</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2018.08.078</pub-id><pub-id pub-id-type="pmid">30153598</pub-id></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pomeroy</surname><given-names>JL</given-names></name>
<name name-style="western"><surname>Marmura</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Nahas</surname><given-names>SJ</given-names></name>
<etal>et al</etal>
</person-group><article-title>Ketamine Infusions for Treatment Refractory Headache</article-title><source>Headache</source><year>2017</year><volume>57</volume><fpage>276</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1111/head.13013</pub-id><pub-id pub-id-type="pmid">28025837</pub-id></element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Schwenk</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Dayan</surname><given-names>AC</given-names></name>
<name name-style="western"><surname>Rangavajjula</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Ketamine for Refractory Headache: A Retrospective Analysis</article-title><source>Reg Anesth Pain Med</source><year>2018</year><volume>43</volume><fpage>875</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/AAP.0000000000000827</pub-id><pub-id pub-id-type="pmid">29923953</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Afridi</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Giffin</surname><given-names>NJ</given-names></name>
<name name-style="western"><surname>Kaube</surname><given-names>H</given-names></name>
<etal>et al</etal>
</person-group><article-title>A randomized controlled trial of intranasal ketamine in migraine with prolonged aura</article-title><source>Neurology (ECronicon)</source><year>2013</year><volume>80</volume><fpage>642</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182824e66</pub-id><pub-id pub-id-type="pmid">23365053</pub-id></element-citation></ref><ref id="R142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lauritsen</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Mazuera</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></name>
<etal>et al</etal>
</person-group><article-title>Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series</article-title><source>J Headache Pain</source><year>2016</year><volume>17</volume><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.1186/s10194-016-0700-3</pub-id><pub-id pub-id-type="pmid">27878523</pub-id><pub-id pub-id-type="pmcid">PMC5120050</pub-id></element-citation></ref><ref id="R143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mendelson</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Kohan</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Okai</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>Adverse drug effects related to multiday ketamine infusions: multicenter study</article-title><source>Reg Anesth Pain Med</source><year>2020</year><volume>45</volume><fpage>684</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1136/rapm-2019-101173</pub-id><pub-id pub-id-type="pmid">32054666</pub-id></element-citation></ref><ref id="R144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Noppers</surname><given-names>IM</given-names></name>
<name name-style="western"><surname>Niesters</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Aarts</surname><given-names>LPHJ</given-names></name>
<etal>et al</etal>
</person-group><article-title>Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: A report of 3 cases</article-title><source>Pain</source><year>2011</year><volume>152</volume><fpage>2173</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2011.03.026</pub-id><pub-id pub-id-type="pmid">21546160</pub-id></element-citation></ref><ref id="R145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Niesters</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Martini</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Dahan</surname><given-names>A</given-names></name>
</person-group><article-title>Ketamine for chronic pain: risks and benefits</article-title><source>Brit J Clinical Pharma</source><year>2014</year><volume>77</volume><fpage>357</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1111/bcp.12094</pub-id><pub-id pub-id-type="pmcid">PMC4014022</pub-id><pub-id pub-id-type="pmid">23432384</pub-id></element-citation></ref><ref id="R146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Schwenk</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Goldberg</surname><given-names>SF</given-names></name>
<name name-style="western"><surname>Patel</surname><given-names>RD</given-names></name>
<etal>et al</etal>
</person-group><article-title>Adverse Drug Effects and Preoperative Medication Factors Related to Perioperative Low-Dose Ketamine Infusions</article-title><source>Reg Anesth Pain Med</source><year>2016</year><volume>41</volume><fpage>482</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/AAP.0000000000000416</pub-id><pub-id pub-id-type="pmid">27281730</pub-id></element-citation></ref><ref id="R147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cohen</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Bhatia</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Buvanendran</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists</article-title><source>Reg Anesth Pain Med</source><year>2018</year><volume>43</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1097/AAP.0000000000000808</pub-id><pub-id pub-id-type="pmcid">PMC6023575</pub-id><pub-id pub-id-type="pmid">29870458</pub-id></element-citation></ref><ref id="R148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Elia</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Tramèr</surname><given-names>MR</given-names></name>
</person-group><article-title>Ketamine and postoperative pain--a quantitative systematic review of randomised trials</article-title><source>Pain</source><year>2005</year><volume>113</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2004.09.036</pub-id><pub-id pub-id-type="pmid">15621365</pub-id></element-citation></ref><ref id="R149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Handa</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Nishikawa</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: a randomized, double-blind, placebo-controlled study</article-title><source>J Clin Anesth</source><year>2000</year><volume>12</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/s0952-8180(99)00131-2</pub-id><pub-id pub-id-type="pmid">10773503</pub-id></element-citation></ref><ref id="R150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Liebe</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Lord</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial</article-title><source>Int J Neuropsychopharmacol</source><year>2017</year><volume>20</volume><fpage>909</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1093/ijnp/pyx055</pub-id><pub-id pub-id-type="pmid">29099972</pub-id><pub-id pub-id-type="pmcid">PMC5737852</pub-id></element-citation></ref><ref id="R151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Giamberardino</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Affaitati</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Costantini</surname><given-names>R</given-names></name>
<etal>et al</etal>
</person-group><article-title>Acute headache management in emergency department. A narrative review</article-title><source>Intern Emerg Med</source><year>2020</year><volume>15</volume><fpage>109</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s11739-019-02266-2</pub-id><pub-id pub-id-type="pmid">31893348</pub-id></element-citation></ref><ref id="R152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tepper</surname><given-names>SJ</given-names></name>
</person-group><article-title>Opioids Should Not Be Used in Migraine</article-title><source>Headache</source><year>2012</year><volume>52</volume><fpage>30</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2012.02140.x</pub-id><pub-id pub-id-type="pmid">22540203</pub-id></element-citation></ref><ref id="R153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tornabene</surname><given-names>SV</given-names></name>
<name name-style="western"><surname>Deutsch</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Davis</surname><given-names>DP</given-names></name>
<etal>et al</etal>
</person-group><article-title>Evaluating the Use and Timing of Opioids for the Treatment of Migraine Headaches in the Emergency Department</article-title><source>J Emerg Med</source><year>2009</year><volume>36</volume><fpage>333</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jemermed.2007.07.068</pub-id><pub-id pub-id-type="pmid">18280084</pub-id></element-citation></ref><ref id="R154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Levin</surname><given-names>M</given-names></name>
</person-group><article-title>Approach to the Workup and Management of Headache in the Emergency Department and Inpatient Settings</article-title><source>Semin Neurol</source><year>2015</year><volume>35</volume><fpage>667</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1564300</pub-id><pub-id pub-id-type="pmid">26595867</pub-id></element-citation></ref></ref-list></back></article>